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IV. ABSTRACT 
Chlamydia trachomatis (Ctr), an obligate intracellular gram negative human pathogen, causes 
sexually transmitted diseases and acquired blindness in developing countries. The infectious 
elementary bodies (EB) of Ctr involved in adherence and invasion processes are critical for 
chlamydial infectivity and subsequent pathogenesis which requires cooperative interaction of 
several host cell factors. Few receptors have been known for this early event, yet the molecular 
mechanism of these receptors involvement throughout Ctr infection is not known.  
Chlamydial inclusion membrane serves as a signaling platform that coordinates Chlamydia-host 
cell interaction which encouraged me to look for host cell factors that associates with the 
inclusion membrane, using proteome analysis. The role of these factors in chlamydial replication 
was analyzed by RNA interference (RNAi) (in collaboration with AG Thomas Meyer). 
Interestingly, EphrinA2 receptor (EphA2), a cell surface tyrosine kinase receptor, implicated in 
many cancers, was identified as one of the potential candidates. Due to the presence of EphA2 
in the Ctr inclusion proteome data, I investigated the role of EphA2 in Ctr infection. 
EphA2 was identified as a direct interacting receptor for adherence and entry of C. trachomatis. 
Pre-incubation of Ctr-EB with recombinant human EphA2, knockdown of EphA2 by siRNA, 
pretreatment of cells with anti-EphA2 antibodies or the tyrosine kinase inhibitor dasatinib 
significantly reduced Ctr infection. This marked reduction of Ctr infection was seen with both 
epithelial and endothelial cells used in this study. Ctr activates EphA2 upon infection and 
invades the cell together with the activated EphA2 receptor that interacts and activates PI3K 
survival signal, promoting chlamydial replication. EphA2 upregulation during infection is 
associated with Ctr inclusion membrane inside the cell and are prevented being translocated to 
the cell surface. 
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Ephrins are natural ligands for Ephrin receptors that repress the activation of the PI3K/Akt 
pathway in a process called reverse signaling. Purified Ephrin-A1, a ligand of EphA2, strongly 
interferes with chlamydial infection and normal development, supporting the central role of these 
receptors in Chlamydia infection. Overexpression of full length EphA2, but not the mutant form 
lacking the intracellular cytoplasmic domain, enhanced PI3K activation and Ctr infection. Ctr 
infection induces EphA2 upregulation and is mediated by activation of ERK signaling pathway. 
Interfering with EphA2 upregulation sensitizes Ctr-infected cells to apoptosis induced by tumor 
necrosis factor-alpha (TNF-α) suggesting the importance of intracellular EphA2 signaling.  
Collectively, these results revealed the first Ephrin receptor “EphA2” that functions in promoting 
chlamydial infection. In addition, the engagement of a cell surface receptor at the inclusion 
membrane is a new mechanism how Chlamydia subverts the host cell and induces apoptosis 
resistance. By applying the natural ligand Ephrin-A1 and targeting EphA2 offers a promising 
new approach to interfere with Chlamydia infection. Thus, the work provides the evidence for a 
host cell surface tyrosine kinase receptor that is exploited for invasion as well as for receptor-
mediated intracellular signaling to facilitate the chlamydial replication. 
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V.  ZUSAMMENFASSUNG 
Chlamydia trachomatis (Ctr) ist ein obligat intrazellulär lebendes Gram negatives Bakterium, 
das Geschlechtskrankheiten verursachen kann. In Entwicklungsländern führt es zudem häufig 
zu erworbener Blindheit. Die infektiösen Elementarkörper (EB) sind für die Anheftung an die 
Wirtszelle sowie die Aufnahme von Ctr in die Wirtzelle verantwortlich. Dies ist ein wichtiger 
Schritt, da nur so die sich anschließende Krankheitsentwicklung stattfinden kann. Diese ist auch 
abhängig vom engen Zusammenspiel der Ctr Proteine mit den Wirtszellfaktoren. Obgleich 
dieser Schritt so wichtig ist, wurden erst wenige  Wirtszellrezeptoren gefunden und welche Rolle 
diese Rezeptoren im weiteren Verlauf der Infektion spielen, ist noch nicht richtig verstanden. 
Die chlamydiale Inklusionsmembran fungiert als Signalplattform, die das  Zusammenspiel von 
Chlamydien und Wirtszelle koordiniert. In dieser Arbeit wurden die Wirtszellproteine, die an der 
Inklusionsmembran lokalisiert sind, mit Hilfe einer Proteomanalyse identifiziert. Anschließend 
wurde die Rolle dieser Proteine bei der Chlamydienvermehrung in einem RNAi screen 
untersucht (in Zusammenarbeit mit der AG Thomas Meyer). Hier wurde überraschenderweise 
der EphrinA2 Rezeptor, eine sich auf der Oberfläche der Zellen befindliche Rezeptor Tyrosin 
Kinase, die vor allem mit Krebs in Verbindung gebracht wird, als ein potentieller Kandidat 
identifiziert. Da die Proteomdaten gezeigt haben, dass EphrinA2 an der Inklusionsmembran 
lokalisiert ist, wurde die Rolle von EphrinA2 während der Ctr Infektion hier näher untersucht. 
Es konnte gezeigt werden, dass EphrinA2 ein direkter Rezeptor für Ctr ist, der sowohl die 
Adhärenz als auch die Aufnahme von Ctr in die Wirtszelle bewerkstelligt. Vorinkubation von Ctr-
EB mit rekombinantem menschlichen EphrinA2, das herunterregulieren von EphrinA2 mit Hilfe 
einer siRNA oder das Vorinkubieren der menschlichen Zelle mit Antikörpern gegen EphrinA2 
oder dem Tyrosinkinase Inhibitor Dasatinib, reduzierten die Ctr Infektion signifikant. Diese 
drastische Reduktion der Ctr Infektion wurde sowohl in Epithelzellen als auch in Endothelzellen 
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beobachtet. Ctr aktiviert EphrinA2 während der Infektion und invadiert die Wirtszelle zusammen 
mit dem aktivierten Rezeptor, dieser interagiert mit dem aktivierten PI3K Überlebenssignal, was 
die Replikation der Chlamydien ermöglicht. An der Inklusionsmembran akkumuliert EphrinA2, 
da der Transport von neuem Rezeptor zur Zellmembran unterbunden ist. Ephrine sind die 
natürlichen Liganden der Ephrinrezeptoren, sie unterdrücken die Aktivierung des PI3K/Akt 
Signalweges in einem Prozess, der reverse Signalübertragung genannt wird.  
Aufgereinigtes Ephrin-A1, ein Ligand des EphrinA2 Rezeptors, verhindert eine normale 
Chlamydieninfektion, was eine zentrale Rolle dieses Rezeptors weiterhin bestätigt. Die 
Überexpression von EphrinA2, erhöhte die PI3K Aktivierung und Ctr Infektion. Dies war nicht 
der Fall, wenn eine Mutante, der die intrazelluläre Domäne fehlt, überexprimiert wurde. Eine Ctr 
Infektion induziert die Hochregulierung von EphrinA2, welche durch die Aktivierung des ERK 
Signalwegs bewerkstelligt wird. Wenn die Hochregulierung von EphrinA2 verhindert wird, 
werden Ctr infizierte Zellen sensitiver für Apoptose induziert durch tumor necrosis factor-alpha 
(TNF-α), was ein weiter Hinweis für die Bedeutung der intrazellulären EphrinA2 
Signalübermittlung ist. 
Insgesamt haben diese Ergebnisse den ersten Ephrin Rezeptor "EphA2" offenbart, der in der 
Förderung chlamydialer Infektionen fungiert. Hinzu kommt, dass die Bindung eines 
Oberflächenrezeptors an die Inklusionsmembran ein neuer Mechanismus ist, die Wirtszelle zu 
verändern und eine Apoptoseresistenz in der Zelle zu induzieren. Die Zugabe des natürlichen 
Liganden Ephrin-A1 eröffnet eine neue vielversprechende Möglichkeit Chlamydieninfektionen 
zu bekämpfen. Daher liefert diese Arbeit erste Hinweise, das eine Wirtszelltyrosinkinase, die 
sich an der Zelloberfläche befindet, notwendig ist für die Invasion und die intrazelluläre 
Signalübermittlung, welche für die chlamydiale Replikation notwendig ist, essentiell ist. 
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1. INTRODUCTION 
1.1. Chlamydiales 
Chlamydia, an obligate intracellular, gram-negative human pathogen, displays a unique biphasic 
developmental life cycle and infects a variety of organisms [1]. Chlamydia cause a wide range of 
severe human diseases, such as infections of the urogenital tract, the eye causing a 
preventable blindness called trachoma and also in the lung causing respiratory tract diseases 
[2]. Chlamydia interferes with several host signaling pathways and accomplish their intracellular 
lifestyle successfully by acquiring nutrients and signals from the host cell [3]. Therefore, a broad 
analysis of how Chlamydia makes their association and replication with and within the host have 
to be investigated which is of strong scientific interest. 
1.1.1. Taxonomy of Chlamydia 
The order Chlamydiales is subdivided into four families based on the taxonomic analysis of 16S 
and 23S rRNA genes including Chlamydiaceae, Parachlamydiaceae, Waddliaceae and 
Simkaniaceae [4, 5]. The family Chlamydiaceae is subdivided into two genera, Chlamydophila 
and Chlamydia encompassing nine species, which include the most important human 
pathogenic species especially Chlamydia trachomatis, the infectious agent associated with 
blindness and Chlamydophila pneumoniae, the major cause of pneumonia (Figure 1.1). Three 
new non Chlamydiaceae families like the Parachlamydiaceae, Waddliaceae and Simkaniaceae 
were also added as drawn below. Different species in the order Chlamydiales, their specific host 
and mode of entry are listed out in the table 1.1. 
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Figure 1.1. Taxonomy of the order Chlamydiales (adapted from [4]). The phylogenetic tree of the 
order Chlamydiales consisting of four families: Chlamydiaceae, Parachlamydiaceae, Waddliaceae 
and Simkaniaceae. The family Chlamydiaceae is divided into the two genera Chlamydophila and 
Chlamydia. The genus Chlamydia is divided into C. trachomatis, C. suis and C. muridarum. The 
lengths of the lines do not represent the actual phylogenetic distance. 
Species Host Entry route 
C. muridarum Mouse, Hamster Pharyngeal, genital 
C. suis Swine Pharyngeal 
C. trachomatis Human Pharyngeal, ocular, genital, rectal 
C. pneumoniae Human, Frog, Koala, Horse Pharyngeal, ocular 
C. caviae Guinea pig Pharyngeal, ocular, genital, urethal 
C. psittaci Birds Pharyngeal, ocular, genital 
C. abortus Mammals Oral, genital 
C. felis Cat Pharyngeal, ocular, genital 
C. pecorum Mammals Oral 
S. negevensis Ameoba, Human Pharyngeal 
Table 1.1. List of species in the genus Chlamydia, their specific hosts and mode of entry (adapted 
from [6]). 
INRODUCTION 
25 
 
1.1.2. Pathology of Chlamydia 
The two most important human pathogens of the order Chlamydiales are C. trachomatis and C. 
pneumoniae. 
Chlamydia trachomatis (Ctr) is a leading cause of most common sexually transmitted diseases 
affecting about 90 million new cases each year worldwide [7], as well as potentially blinding 
trachoma affecting 50 million people with 1.3 million of them causing blindness [8]. Based on the 
immunogenic epitope analysis of the major outer membrane protein (MOMP) of C. trachomatis 
with polyclonal and monoclonal antibodies, Ctr is classified into 15 serologically distinguished 
serovars [9, 10]. These serovars can be divided into two biovars called trachoma and 
lymphogranuloma venereum (LGV). The trachoma serovars from A-C invades mucosal epithelia 
in the ocular tissue which can lead to blinding trachoma and are transmitted by direct contact 
with eye, nose or throat secretions from infected individuals. If not treated with antibiotics, 
chronic infection can lead to eyelid scarring and subsequent blindness causing severe 
inflammatory response [11]. The serovars from D-K infect mucosal epithelial cells of the 
urogenital tract causing pelvic inflammatory disease (PID), ectopic pregnancy and infertility [12-
14]. The LGV serovars L1, L2 and L3 are more invasive and cause outbreaks of systemic 
infections in humans by invading lymph nodes thereby causing the sexually transmitted 
systemic syndrome lymphogranuloma venereum (LGV) [15, 16]. 
The species C. pneumoniae cause human respiratory tract diseases by infecting epithelial cells 
of the upper and lower respiratory tract [17, 18]. It is transmitted by droplet infection while in 
70% of the cases the infection is asymptomatic [19, 20]. C. pneumoniae is also responsible for 
infections including pharyngitis, sinusitis, otitis, acute bronchitis, persistent cough, chronic 
obstructive pulmonary disease and Flu like syndrome [21]. The symptoms of an acute infection 
can range from a minor cold to a serious pneumonia while chronic infection are associated with 
asthma [22], atherosclerosis [23] or Alzheimer’s disease [24]. 
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If these Chlamydia infections are detected at proper time, they can be effectively treated with 
antibiotics including tetracyclines (doxycycline, tetracycline, etc), macrolides (azithromycin, 
clarithromycin, erythromycin, etc) and quinolones (Centers for Disease Control and Prevention, 
2010, http://www.cdc.gov/std/treatment/2010/chlamydial-infections.htm). But as the infected 
people are often asymptomatic, the infections are not diagnosed which leads to such serious 
complications. Therefore, awareness should rise for education on having protected sexual 
intercourse as well as active screening for chlamydial infections [25]. 
1.1.3. Life cycle of Chlamydia trachomatis 
The unique biphasic life cycle of Chlamydia includes a characteristic intracellular reproduction 
within a membrane-surrounded protective compartment termed “inclusion”. Electron microscope 
studies showed that two morphologically and structurally distinct development forms, the so-
called elementary bodies (EB) and reticulate bodies (RB) exist [26] (Figure 1.2).  
 
Figure 1.2. Transmission electron microscopic image of a HeLa cell-infected with Chlamydia MOI-
1 for 24 h: The image of the inclusion with EB (Elementary body), RB (Reticulate body) and M 
(Mitochondria) inside the cell was magnified on the right hand side. Bars represent 2 μm at 
magnification 6000× (left image) and 8000× (right image). 
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The small metabolically inactive EB (0.3 µm) are osmotically stable and resistant to extracellular 
environmental stress. It binds and infects most of the cultured human cells [27]. Infection starts 
with the EB binding to the host cell membrane via electrostatic interaction with heparan 
sulphate-like glycosaminoglycans, followed by a more specific attachment to host cell receptor. 
Attachment is followed by uptake of the infectious particles inside the cell (endocytosis) (Figure 
1.3). Within the cell and inside the inclusion, EB develops into the metabolically active, 
replicating but non-infectious RB with a size of approximately 1 µm [28]. To cause an acute 
infection, after numerous rounds of replication by binary fission, RB re-differentiate back into 
infectious EB that are released from the cell to infect new cells and thereby enter a new life 
cycle [1] (Figure 1.3). The signals inducing for the transition from EB to RB and later from RB to 
EB are not known. In reaction to external stimuli, such as interferon gamma (IFN-γ), penicillin, 
amino acid- or iron-starvation, the chlamydial development cycle can descend into persistence 
[29, 30]. In the persistence stage, the RB develop into aberrant bodies (AB), where the host cell 
is not lysed and only few infectious particles are produced [31]. In the absence of external 
stimuli, the EB converts back into RB which can lead to an acute infection. 
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Figure 1.3. Developmental cycle of Chlamydia: The life cycle of C. trachomatis starts with the 
attachment of EB on the host cell surface receptors which is followed by invasion. After 
internalization, Ctr develops an inclusion followed by the differentiation of EB into RB. RB 
multiply inside the inclusion by binary fission followed by its re-differentiation into EB. After 48 h, 
the EB are released from the host cell though cell lysis in order to start a new round of infection 
(Modified from http://sahsrojas.pbworks.com/w/page/3695831/chlamidia). 
1.2. Pathogen-Host interaction 
1.2.1. Chlamydia-Host cell surface interaction 
Chlamydia communication with the host is absolutely essential for their survival. Attachment of 
EB to the surface of the host cell initiates the infection. Like in other gram negative bacteria, the 
presence of a type III secretion system (T3SS) was confirmed by sequencing the chlamydial 
genomes [32]. The genomic arrangement of the T3SS genes differs in comparison to other 
gram-negative bacteria. Chlamydia entry into the cells is multifaceted process generally initiated 
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by the molecular interactions that occur between various Chlamydia factors secreted by T3SS 
or the outer membrane proteins which can interact with cell surface exposed receptor/co-
receptor molecules and are fundamental to pathogenesis. Some of the chlamydial factors like 
major outer membrane protein [33], glycosaminoglycans [34], Hsp70 heat shock protein 70 [35], 
translocated actin recruiting phosphoprotein (TARP) [36, 37] and OmcB [38] whereas several 
host surface proteins like epithelial membrane protein 2 [39], the estrogen receptor complex [40] 
and its subunit protein disulfide isomerase (PDI) [40, 41] are known to be involved in the 
chlamydial adherence. In addition, receptor tyrosine kinases (RTKs) also play an important role 
in a wide range of signaling processes in development. Several host cell tyrosine kinases and 
their associated intracellular signaling cascades are known to play a pivotal role in facilitating 
Chlamydia adherence and regulating its infection. The host tyrosine kinase platelet-derived 
growth factor receptor (PDGFR) and Abl kinase are involved in the chlamydial uptake into non-
phagocytic cells [37]. Another tyrosine kinase receptor, fibroblast growth factor receptor (FGFR), 
is activated upon Chlamydia infection and are recruited to the cell surface associated Chlamydia 
[42]. Chlamydia induce their uptake into non-phagocytic cells through small-GTPase dependent 
reorganization of the actin cytoskeleton [43]. 
1.2.2. Intracellular biology of chlamydial proteins and its interaction with host 
proteins 
The T3SS of Chlamydia secretes several membrane proteins (Inc) that are anchored on its 
inclusion membrane which interact with host proteins in order to attain nutrients and lipids for 
the inclusion growth thereby ensuring its intracellular replication. Chlamydial inclusion proteins 
help RB to acquire iron and nutrients from the host [44]. Some of the well-studied Inc proteins 
are IncA, IncD and IncG. A snare motif is seen in the protein sequence of IncA which can form 
stable tetramers capable of fusing Ctr inclusions. The cytosolic portion of IncA interacts with 
IncA on other inclusion membranes enabling homotypic vesicle fusion [45]. Thus, IncA proteins 
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are important in eukaryotic compartment fusion and is able to recruit a subset of host SNARES 
like Vamp 8, Vamp 7 and Vamp 3 which leads to the selective recruitment of intracellular 
compartments around the inclusion thereby controlling the intracellular trafficking by mimicking 
SNAREs [46]. Apart from IncA, there is another Inc protein called Ct229 which can also perform 
such type of vesicle fusion [47].  
Some Inc proteins were identified to interact with Rab GTPases and thereby selectively 
recruiting them to the inclusion, e.g. Rab4, Rab11, Rab1, Rab14 and Rab6 [48, 49]. Ctr is able 
to intercept trafficking vesicles via the recruitment of Rab proteins, which are able to specifically 
snatch vesicles from the retrograde intra-Golgi trafficking or interact with host organelles, such 
as the endoplasmic reticulum (ER). Several Inc proteins also associate with active Src family 
kinases, thereby regulating the interaction with the microtubule network and the acquisition of 
sphingolipids [47, 50]. 
Eukaryotic protein 14-3-3β, whose functions are involved in the regulation of apoptosis, cell 
cycle and cell differentiation, is found to interact with the cytosplasmically exposed caroxy-
terminal domain of the chlamydial protein IncG which is confirmed in infected HeLa cells by 
indirect immunofluorescence microscopy [51]. Also the interaction level is dependent on the 
phosphorylation state of IncG which is phosphorylated by host or chlamydial-derived kinases. 
Since IncG was phosphorylated by yeast kinases via yeast hybrid system, signifying that 
eukaryotic kinases are capable of phosphorylating IncG allowing the specific interaction with 14-
3-3β. Ser-166 of IncG is essential for the interaction between IncG and 14-3-3β as the mutation 
of Ser-166 to Ala completely inhibits the binding to 14-3-3β. The group found large amounts of 
14-3-3β localized into the inclusion membrane during chlamydial infection and so the levels in 
the cytoplasm are reduced possibly altering the host signal pathway [51]. The importance of 14-
3-3β binding to inclusion in the pathogenesis of chlamydial infection remains to be established. 
By recruiting 14-3-3β, the ligands of 14-3-3β could be recruited to the inclusion thereby 
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transducing some unknown signal from the cytoplasm to the interior of the inclusion and vice 
versa.  
Another Ctr inclusion membrane protein IncD interacts with ER to Golgi ceramide transfer 
protein called CERT which partly co-localize with an ER protein-Vamp-associated protein B 
(VAPB) thereby exploiting the host non-vesicular lipid transport machinery [52]. Other than the 
inclusion membrane proteins Chlamydia can also secrete cytosolic effector proteins like CT671, 
CADD and many others localized to the cytosol of the host cell thereby interacting with the 
eukaryotic factors [53, 54]. Thus, Chlamydia intercepts numerous host trafficking pathways 
during infection to get lipids, amino acids, nucleotides and other nutrients (reviewed in [3]). The 
membrane covering the inclusion of Chlamydia protects the pathogen and helps their interaction 
with the host cells to accomplish their biosynthesis, replication and differentiation within the 
inclusion. 
1.2.3. Chlamydia and cell survival pathways 
Chlamydia acquires nutrients and lipids, prevents lysosomal fusion and escapes from host 
immune response as well as from cell death by hijacking several host signaling pathways mainly 
mitogen-activated protein kinases (MAPK) and phosphoinositol 3-kinase (PI3K) as shown in 
figure 1.4. Both these pathways are important in modulating host cell apoptosis and cell survival 
during C. trachomatis infection [55-58].  
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Figure 1.4. Exploitation of host cell by Chlamydia: C. trachomatis secretes inclusion membrane 
(Inc) proteins and other effector proteins though T3SS to interfere with several host cell pathways 
like PI3K-Akt and RAF-MAPK in order to acquire nutrients, overcome host defense and support 
the survival of the host cell. 
1.2.3.1. MAPK pathway 
MAPK are protein kinases that are important in regulating several cellular functions such as 
proliferation, gene expression, differentiation, mitosis, cell survival and apoptosis [59-61]. This 
pathway is activated by several events including a wide variety of receptors like receptor 
tyrosine kinases (RTKs), integrins and ion channels. A set of adaptors like Shc, GRB2 and Crk 
that links the receptor to a guanine nucleotide exchange factor and transduce the signal to small 
GTP-binding proteins like RAS and Rap1, which then activates cascade composed of a 
MAPKKK (RAF), a MAPKK (MEK1/2) and MAPK (ERK) (cell signaling pathway [62]). An 
activated ERK dimer translocate to the nucleus where it phosphorylates a variety of transcription 
factors regulating the gene expression [63] (Figure 1.5). 
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Figure 1.5. RAS/RAF/MEK/ERK pathway: The chronological phosphorylation of RAS-RAF-MEK-
ERK, after dimerization of RTK upon ligand binding. The ERK cascade is constituted by RAS, 
RAF, MEK and ERK proteins. After the binding of the extracellular peptide with the RTK and its 
dimerization, it activates the RAS protein, which then activates the RAF family, MEK and, finally, 
ERK protein which regulates the gene expression by phosphorylating the transcription factors 
(modified-http://www.intechopen.com/books/). 
Chlamydial efficient internalization and anti-apoptotic activity involves the activation of the 
MEK/ERK survival pathway. Inhibition of the pathway sensitized Chlamydia-infected cells to 
STS-mediated cell apoptosis [64]. The activation of ERK during Chlamydia infection is followed 
by the downstream regulation of several molecules like cPLA2, required for the chlamydial 
uptake of host glycerophospholipids [65] and also for regulating the intracellular immunity to 
Chlamydia [66]. Ctr-mediated ERK activation also leads to the time-dependent induction of 
interleukin-8 (IL-8) [67, 68], shedding of TNF receptor 1 (TNFR1) [69] and anti-apoptotic Mcl-1 
stabilization [70]. Further, stimulation of fibroblast growth factor 2 (FGF2) [42] and induction of 
anti-apoptotic Bcl-2-associated athanogene-1 (Bag-1) [71] are also associated with ERK 
activation during Ctr infection which are necessary for the intracellular development.  
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1.2.3.2. PI3K pathway 
Another pathway that plays a major role in protecting Chlamydia from apoptosis is PI3K 
pathway [58]. Akt or Protein Kinase-B (PKB), downstream of PI3K, is a serine/threonine kinase 
involved in mediating various biological responses like inhibition of apoptosis and stimulation of 
cell proliferation [72, 73]. Activation of Akt begins with the binding of a ligand to a receptor in the 
cell membrane. The ligands like growth factors, cytokines, mitogens, hormones, insulin and a 
variety of growth factors binds to RTK and causes autophosphorylation of tyrosine residues on 
the intracellular domain of the receptor. PI3K is therefore targeted to the inner cell membrane. 
PI3K is composed of a p110 catalytic subunit and a p85 regulatory subunit. Binding of p85 
subunit of PI3K (p85-PI3K) to the phosphorylated RTK leads to conformational changes in the 
catalytic domain of PI3K (p110) and results in kinase activation. PI3K phosphorylates 
membrane bound PIP2 to PIP3 (Figure 1.6). Binding of PIP3 to the PH domain anchors Akt to 
the plasma membrane and allows its phosphorylation and subsequent activation [74-78]. The 
physiological roles of Akt include involvement in transcription factor regulation, metabolism, 
protein synthesis, cell cycle and apoptosis pathways [79, 80].  
Akt applies its effects in the cell by phosphorylating a variety of downstream substrates most 
particularly Bcl-2 antagonist of cell death (BAD) [81], glucose transporters (GLUTs) [82], nitric 
oxide synthase (eNOS) [83], mammalian target of rapamycin (mTOR) [84], I-κB kinase (IKK), 
nuclear factor-κB (NF-κB) [85], Caspase 9 [86], MDM2 [87] and Glycogen Synthase Kinase-3 
(GSK3) [84]. Briefly, Akt inhibits apoptosis by phosphorylating the BAD component of the Bcl-2 
related protein long isoform complex (BAD/BclXL) which binds to 14-3-3 causing dissociation of 
the BAD/BclXL complex and allowing cell survival. Akt activates IKK, which leads to NF-κB 
activation leading to cell survival. Caspase9 is one of the notable substrates of Akt. 
Phosphorylation of Caspase9 at Ser136 by Akt decreases apoptosis by directly inhibiting the 
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protease activity. Akt also activates glycogen synthesis by phosphorylating and inactivating 
GSK3, which leads to the activation of glycogen synthase and CyclinD1. Akt phosphorylates 
human form of murine double minute 2 [MDM2]) (HDM2) allowing its entry into the nucleus 
where it targets the tumor suppressor protein p53 for degradation. The actions of Akt in the cell 
are abundant and diverse, nevertheless all results in anti-apoptosis or pro-cell proliferation 
effects.  
 
Figure 1.6. PI3K/Akt pathway: PI3K is activated after ligand binding to a receptor. The p110 
subunit of PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to PIP3 which 
recruits Akt to the plasma membrane and results in the activation of PDK1 and Akt proteins which 
regulates a huge number of downstream targets. The phosphatase and tensin (PTEN) analog 
protein acts as a repressor by de-phosphorylating PIP3 to PIP2 and inhibiting the Akt activation 
(adapted from-[88]). 
Chlamydia infection induces PI3K activation which is important for the subsequent 
phosphorylation and activation of downstream effector Akt. Activation of Akt leads to 
phosphorylation of Bad which is sequestrated by 14-3-3β on the surface of chlamydial inclusion 
(Figure 1.7). Chlamydia infection mediates the degradation of most of the unphosphorylated 
Bad but remaining Bad is sequestrated away from mitochondria by 14-3-3β to the Chlamydia 
inclusion membrane protein IncG. Thus, expression of IncG on Chlamydia inclusion and binding 
of 14-3-3β by IncG allows the inclusion to recruit phosphorylated Bad preventing the ability of 
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remaining bad to translocate to the mitochondria and induce host cell death [51, 89]. Further, 
Chlamydia infection leads to the MEK-dependent up-regulation of Mcl-1 transcription and PI3K-
dependent stabilization of Mcl-1 protein levels. Interfering with Mcl-1 levels sensitizes infected 
cells to apoptosis [70]. Recently, it was found that chlamydial infection downregulates host p53 
and this reduction is mediated by the PI3K/Akt signaling pathway which activates HDM2 and 
subsequent proteasomal degradation of p53 [90]. p53 inhibits glucose 6 phosphate 
dehydrogenase activity, the first rate limiting step in pentose phosphate pathway [91]. Thus, p53 
stabilization impairs chlamydial development due to lack of metabolic support, as Chlamydia 
entirely depend on the uptake of amino acids and nucleotides from the host [92]. 
 
Figure 1.7. Schematic demonstration on the effects of Akt activation during Chlamydia infection. 
Dephosphorylated Bad forms heterodimer complex with Bcl-2/Bcl-xL inactivating them and 
allowing Bax/Bak triggered apoptosis under stress conditions. During Chlamydia infection, Bad is 
phosphorylated by activated Akt and the phosphorylated Bad gets dissociated from Bcl-2/Bcl-xL 
complex releasing them. Phosphorylated Bad is recruited to the Chlamydia inclusion by 14-3-3β. 
The released Bcl-2/Bcl-xL inhibits Bax/Bak triggered intrinsic apoptosis. Akt activation during 
chlamydial infection inactivate GSK3 by phosphorylation which prevents the inhibition of Mcl-1 
that is necessary for resisting apoptosis. Further, HDM2 is phosphorylated by activated Akt which 
degrades p53 through preoteosomal degradation necessary for the chlamydial development. 
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1.3. EphA2 receptor 
1.3.1. Structure of Eph receptors and Ephrin ligands 
Eph receptors (Erythropoietin-producing human hepatocellular carcinoma line) are the largest 
subfamily of RTKs having 16 members. They can be divided into two subclasses, EphA and 
EphB which are encoded by the genetic loci designated EPHA and EPHB respectively [93]. 
They are activated in response to binding to Ephrin ligands or Eph family receptor interacting 
proteins which are membrane-bound and interact with an Eph receptor upon cell-to-cell contact 
[94]. Out of the 16 receptors, humans are known to express nine EphA (EphA1-8 and EphA10) 
and five EphB (EphB1-4 and EphB6) [95]. EphA/Ephrin-A interaction occur with higher affinity 
than EphB/Ephrin-B interactions as the former requires only little conformational change 
whereas the latter utilize greater amount of energy to alter the conformation of EphB to bind to 
Ephrin-B [96]. Like other receptor tyrosine kinases, Eph receptors also share a similar structure 
with an extracellular, transmembrane and cytoplasmic portion. The extracellular portion starts 
with Ephrin-binding (ligand binding) globular domain, followed by a cysteine-rich region and two 
fibronectin-type III repeats [96]. The intracellular or the cytoplasmic portion of the receptor 
consists of a juxtamembrane region with two autophosphorylation tyrosine sites, a highly 
conserved tyrosine kinase domain, SAM (sterile alpha motif) and PDZ binding motif [97] (Figure 
1.8). The Ephrin-A and Ephrin-B receptor families, their functions and tissue specificities are 
reviewed in [98].  
The structure of Ephrin is different between Ephrin-A and Ephrin-B. Ephrin-A ligands are 
membrane anchored proteins which do not have a transmembrane region and are linked to the 
membrane by a short glycosylphosphotidylinositol (GPI) anchor. Ephrin-B ligands possess a 
transmembrane region, a cytoplasmic portion containing a phosphorylation site and PDZ 
binding domain. The glycosylphosphatidylinositol-linked Ephrin-A ligands binds to EphA 
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receptors and the transmembrane-bound Ephrin-B ligands binds to EphB receptors [99]. 
Binding of an Ephrin ligand to the extracellular globular domain of an Eph receptor causes 
phosphorylation at the tyrosine and serine residues in the juxtamembrane region of the Eph 
receptor [100] followed by the activation of intracellular tyrosine kinase and consequently 
activate or repress downstream signaling cascades [101]. 
 
Figure 1.8. Schematic representation of Eph receptors and respective ligands [102]. Eph receptor 
possess a highly conserved N-terminal glycosylated extracellular ligand-binding domain, a 
cysteine-rich region, and two ﬁbronectin type III repeats on the extracellular portion. The 
intracellular region is comprised of a juxtamembrane domain, a kinase domain, SAM and PDZ 
binding motif. Ephrin-A ligands are linked to the membrane by a short GPI anchor. Ephrin-B 
ligands possess a transmembrane region and cytoplasmic portion. 
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1.3.2. Eph receptor signaling  
Eph/Ephrin undergoes bidirectional forward and reverse signaling which controls diverse 
signaling pathways and involves crosstalk with other signaling systems like Src family kinases, 
RAS/Rho family GTPases, PI3K/Akt, MEK/ERK and integrins along with the crosstalk of other 
receptors [e.g., Epidermal growth factor receptor (EGFR)]. The forward signaling is mediated by 
the receptor expressing cells whereas reverse signaling is initiated within ligand-expressing 
cells both often mediate opposite effects [103].  
EphrinA2 receptor (EphA2) gene is located on chromosome 1p36. EphA2 is transcribed and 
translated into a 976-amino acid transmembrane glycoprotein (~130 kDa). Ephrin-A1 is a TNF-α 
early-inducible gene product located within chromosomal region 1q21-q22 with the molecular 
mass of 22 kDa and 205-amino acids. In the presence of Ephrin-A1, the receptor EphA2 
tyrosine gets phosphorylated which counteracts the growth factor signaling by inhibiting 
activation of RAF/MEK/ERK and PI3K/Akt and this inhibition is necessary for the maintenance 
of epithelial homeostasis in case of normal conditions as well as during stress conditions [104, 
105]. In the absence of Ephrin-A1, unligated EphA2 signaling takes place and can serve as a 
substrate of Akt where serine residue of EphA2 gets phosphorylated and is incapable of 
suppressing RAS/ERK pathway [106] (Figure 1.9). In addition, the association of EphA2 with 
activated PI3K was extensively studied before. The p85 subunit of PI3K interacts with 
phosphorylated Tyr734 in the kinase domain and Tyr929 in the SAM domain of EphA2 [107]. 
Further, inhibition of EphA2 affects the activation of PI3K/Akt [105, 108, 109]. 
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Figure 1.9. Ligand dependent and independent EphA2 signaling: (adapted from- 
http://www.cellapplications.com/epha2-antibody.php). Ephrin-A1 ligand-mediated activation of 
EphA2 signaling inhibits both RAF/MEK/ERK and PI3K/Akt pathways whereas ligand independent 
EphA2 signaling is important to promote those pathways [105, 110, 111]. ([105]-Bidirectional 
signaling). 
1.3.3. EphA2 role in physiology and cancer 
The role of Eph receptors was extensively studied in the developing nervous system as Eph-
Ephrin bidirectional signaling is important for the communication between neurons and glial cells 
regulating the formation of synaptic connections [112]. Outside of nervous system, Eph-Ephrin 
interaction has been shown to play an important role in the immune system (thymocytes 
differentiation), glucose homeostasis and diabetes (insulin secretion by β cells), repair after 
injury, bone maintenance and remodeling (osteoblast differentiation) and intestinal homeostasis 
(epithelial cell differentiation and migration) (reviewed in [113]). Thus, Eph/Ephrin signaling 
regulates multiple host cell processes most notably involving embryonic axon guidance, 
angiogenesis, cell death, migration and differentiation in development and cancer [113-118].  
Of all Eph receptors, EphA2 is the most studied receptor and has generated greatest interest in 
the recent years due to its increased expression (both mRNA and protein) levels seen in a 
variety of human malignancies like ovary [119, 120], breast [121], cervix [122], kidney [123], 
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prostate [124, 125], bladder [126], lung [127], esophagus [128], colon [129], stomach [130],  and 
pancreas [131]. High expression of EphA2 is also detected in melanomas [132] and 
glioblastomas [133-135] with poor diagnosis and decreased survival [123, 126, 136, 137]. 
Additionally, expression of Ephrin-A1 ligand was suppressed by the activation of oncogenic 
signaling induced by EphA2 overexpression [138] which leads to the disruption of balance of 
EphA2 bi-directional signaling important to maintain the cell homeostasis (Figure 1.10). 
Soluble Ephrin-A1 induces the activation of EphA2 receptor which leads to the suppression of 
RAS-MAPK signaling and therefore inhibits tumor cell growth as well as motility [103]. EphA2 
when overexpressed exhibits low Ephrin-A1 [138, 139]. In contrast, cells that express high 
levels of Ephrin-A1 exhibit low EphA2 and the condition is reversed by siRNA mediated 
knockdown of Ephrin-A1 [138]. EphA2 is a transcriptional target of MAPK pathway and this 
pathway is also involved in the down regulation of Ephrin-A1 [138].  
 
Figure 1.10. Role of EphA2 and Ephrin-A1 signaling in solid tumor cells (adapted from [140]): In 
the absence of Ephrin-A1, EphA2 becomes overexpressed due to increased gene expression. 
Overexpressed EphA2 stimulates migration, invasion and therefore the promotion of 
tumorigenicity. In contrast, the ligand Ephrin-A1 causes EphA2 downregulation contributing to 
the tumor-suppressing effects [103].  
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1.3.4. EphA2 receptor expression and regulation during pathogenic infection 
More has been known concerning EphA2 function in cancer field and very less is known about 
its role in infection. EphA2 and EGFR were proposed as a cellular factors for Hepatitis C Virus 
(HCV) which mediate the viral entry. This demonstrated the importance of RTKs as the host 
factors for HCV entry and possible targets for antiviral therapy [141]. Hepatitis C, caused by the 
HCV, is an infectious disease affecting primarily the liver causing liver cirrhosis and 
hepatocellular carcinoma. Using functional RNAi screen, the group found both EGFR and 
EphA2 as key components due to their high expression in liver. The antibodies specific for 
amino terminal domain of EphA2, EphA2 surrogate ligands and EphA2 inhibitor dasatinib 
impaired HCV entry and infection. Both EphA2 and EGFR are involved in viral glycoprotein- 
dependent membrane fusion, cell to cell transmission and viral dissemination.  
EphA2 was also proposed to be a cellular receptor for Kaposi’s sarcoma-associated herpes 
virus (KSHV) glycoproteins H and L [142]. KSHV causes Kaposi’s sarcoma (KS) [143], a tumor 
originating from lymphatic endothelial cells [144, 145]. EphA2 is co-precipitated with the 
glycoprotein dimeric complex H and L (gH and gL) of KSHV [142] which is required for the entry 
of herpesvirus into the host cells [146]. Binding of gH and gL of KSHV with EphA2 triggered 
EphA2 activation. Moreover, antibodies or siRNA against EphA2, pretreatment of KSHV with 
soluble EphA2 or pretreating the cells with EphA2 ligand inhibited the infection of KSHV, 
whereas EphA2 overexpression enhanced the infection. Ligand binding of EphA2 results in 
receptor clustering and endocytosis. Thus, KSHV may profit through this mechanism by using 
the ligand binding domain of EphA2 to enter the cell.  
Human dermal endothelial cells infection with KSHV interacts with EphA2 and integrins in the 
lipid raft region followed by the viral entry by EphA2 by co-ordinating integrin-c-Cbl associated 
signaling. Further, EphA2 shRNA transduction reduced the phosphorylation of Src and PI3K in 
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KSHV infected endothelial cells which lead to reduced viral entry and infection. Thus, EphA2 
acts as a master assembly regulator of KSHV entry which induces signal molecules and 
regulates KSHV endothelial cell entry [109, 147]. But in human foreskin fibroblast cells, KSHV 
enters by lipid draft independent clathrin mediated endocytosis. During its entry, KSHV induces 
the association of integrins with EphA2 in the non-lipid raft regions and activates EphA2 which 
induces the association with several downstream signaling complexes. Further, c-Cbl directed 
polyubiquitination of EphA2 helps interaction with accessory proteins. These interactions 
promote activation, recruitment and assembly of clathrin to the formation of clathrin coated pits 
and these events trigger the internalization of KSHV. Inhibition of EphA2 reduces the induction 
of these signaling complexes thereby reducing the viral entry and infection [147]. 
EphA2 role is also implicated in Mycobacterium tuberculosis whose infection interferes with host 
immune response by inducing EphA2. EphA2 knockout mice displayed greater pathology, 
higher accumulation of T cells and dendritic cells and also higher levels of proinflammatory 
cytokines, efficient migration of T cells than the wildtype mice. Whereas wildtype mice infection 
showed higher expression of EphA1, EphA2 as well as its ligand indicating that ligand 
dependent signaling turns to be an important mechanism for the survival of Mycobacterium 
tuberculosis during chronic phase of infection. EphA2 signaling appears to vary depending on 
the cell specific environment. Thus, induction of EphA2 is engaged in modulating immune 
response and enhancing the bacterial survival [148]. Another sexually transmitted pathogen, 
Neisseria gonorrhoeae, also induces the expression of Eph receptors like EphA2 and EphA3 in 
epithelial cells upon infection [140], however, the role of these receptors in N. gonorrhoeae 
infection was not examined. 
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2. AIM OF THE WORK  
The current concept on how Ctr communicates with host cell during bacterial replication is 
based on the identification of host proteins that interacts with bacteria. Ctr enter the host cell by 
the molecular interactions that occur between Ctr effectors and cell surface exposed receptor 
molecules. Inside the cell, Ctr releases their virulence factors targeting and hijacking multiple 
host trafficking pathways in order to acquire nutrients and to prevent cell death ensuring its 
intracellular replication. Though few mechanisms on how Chlamydia interferes with certain 
signaling components are identified, but still it seems to be a tricky pathogen to explore. 
Identification and analysis of the host molecular complexes that associate with Ctr inclusion 
would facilitate to understand the mechanisms by which the pathogen effectively manipulates 
the host signaling pathways and escape from the host cell death pathway. Therefore, it is of 
utmost importance to have a global knowledge by investigating the host interacting proteins with 
chlamydial inclusion thereby understanding the crosstalk between Chlamydia and host during 
infection.  
In the first part of my work, intact Ctr inclusions will be isolated from the infected cells and the 
host proteins that were enriched or depleted in the inclusion of Chlamydia will be identified via 
mass spectrometry analysis. Further, the role of those host proteins in chlamydial replication will 
be analyzed by RNAi (in collaboration with AG Thomas Meyer). As a validation study, the 
protein expression pattern of the selected hits will be analyzed by immunoblot studies in time 
course Ctr infection in order to choose a host candidate for further experimental studies to 
identify its crucial role in Ctr infection. Therefore, in the second part of my work, I aimed to 
investigate the role of the chosen host candidate in early infection to find out if the candidate 
plays any potential role in Ctr entry process. Further studies will be conducted, by combination 
of molecular approaches, to investigate the underlying signaling mechanism of the host 
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candidate in mid-phase Ctr infection and the reason behind its enrichment found in inclusion 
proteome data. This work shall give an idea on the role of an unidentified host factor necessary 
for the chlamydial development and infection. 
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3. MATERIALS AND METHODS 
3.1. MATERIALS 
3.1.1. Cell line  
Cell line Feature Origin Source 
HeLa 229 Cervical adenocarcinoma Human ATCC no. CCL-2.1 
 
Table 3.1. Human tissue culture cell line used in the study. 
3.1.2. Primary cells 
Cells Tissue Origin 
HUVEC (Human Umblical 
Vein Endothelial cells) 
Umbilical vein/vascular endothelium Human 
Fimb (Fimbriae of Uterine 
tube Epithelial cells) 
Ovary epithelial cells Human 
 
Table 3.2. Primary cells used in the study. 
3.1.3. Bacterial strains 
Bacteria Serovars Source 
Chlamydia trachomatis LGV L2 (434) ATCC no. VR-902B 
Chlamydia trachomatis D ATCC no. VR-885 
Chlamydia trachomatis A ATCC no. VR-571B 
Chlamydia trachomatis pGFP::SW2 LGV L2 (434) Dr. Adrian Mehlitz 
Chlamydia trachomatis pIncA-flag LGV L2 (434) This work, Prema Subbarayal 
Chlamydia pneumoniae CWL-029 ATCC no. VR‐1310  
 
Table 3.3. Bacterial strains used in the study. 
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3.1.4. Cell culture medium and buffers 
Type Medium 
Hela229 cells 1x RPMI 1640+ L-Glutamax +25 mM HEPES (GIBCO, 
Germany),10% (v/v) heat inactivated FCS (Biochem) 
HUVEC cells RPMI (GIBCO) with 10% FBS and HUVECs cultured in medium 200 
supplemented with low serum growth supplement (LSGS, Gibco BRL) 
Fimb cells 1x RPMI 1640+ L-Glutamax +25 mM HEPES, 10% (v/v) heat 
inactivated FCS  
Bacterial culture media 1x RPMI 1640+ L-Glutamax +25 mM HEPES, 10% (v/v) heat 
inactivated FCS  
Freezing media 1x RPMI 1640+ L-Glutamax +25 mM HEPES, 10% (v/v) heat 
inactivated FCS, 10 % (v/v) DMSO 
Transfection media Cell culture medium + 20% (v/v) Optimem (GIBCO) 
SPG buffer 0.22 M sucrose, 10 mM Na2HPO4, 3.8 KH2PO4, 5 mM glutamate 
PEI stock solution Dissolve PEI powder to a concentration of 2 mg/ml in water which has 
been heated to 80°C. Allow solution to cool to room temperature (RT). 
Adjust pH to 7.0 with 5M HCl. Filter sterilize. Freeze aliquots at -80°C 
 
Table 3.4. List of cell culture medium and buffers used in this study.  
3.1.5. Buffer and Solutions 
3.1.5.1. Buffer for FACS 
Buffers Ingredients 
PBS (1x) (/L) 8 g NaCl, 0.2 g KCl, 2.68 g Na2HPO4 (1x H2O), 0.24g KH2PO4, adjust 
to pH 7.4 
Fixing buffer (/L) 1x PBS + 4% (w/v) PFA, adjust to pH 7.2 
Permeabilisation buffer 1x PBS + 0.2% (v/v) Triton X 100 
Blocking buffer 1x PBS + 10% (v/v) FCS 
 
Table 3.5. Buffers and components used for FACS analysis. 
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3.1.5.2. Buffer for Western blot 
Buffers Ingredients 
10 x SDS buffer (/L) 30.275 g Tris, 144 g glycine, 10 g SDS 
10x Semi dry buffer (/L) 24 g Tris, 113 g glycine, 2 g SDS 
1x Semi dry transfer buffer 1x semi dry buffer + 20% (v/v) methanol 
10x TBS (/L) 60.5 g Tris, 87.6 g NaCl, adjust to pH 7.5 with HCl 
TBST20 1 x TBS + 0.5% (v/v) Tween20 
Blocking solution TBST20 + 5% (w/v) dry milk powder or BSA 
Stripping buffer (500 ml) Prod#46430 Thermo Scientific 
2x Laemmli buffer 100 mM Tris/HCl [pH 6.8], 20% (v/v) glycerol, 4% (w/v) 
SDS, 1.5% (v/v) 2‐mercaptoethanol, bromophenol blue 
10% SDS lower gel solution For 10 ml: 4.15 ml H2O, 3.38 ml 30% (v/v) acrylamid : 
bisacrylamid mix (37.5:1), 2.5 ml 10% (w/v) SDS, 2.5 ml, 
1.5 M Tris/HCl [pH 8.8], 0.1 ml 10% APS, 4 μl TEMED 
SDS upper gel solution For 5 ml: 3.4 ml H2O, 0.83 ml 30% (v/v) acrylamid : 
bisacrylamid mix (37.5:1), 0.63 ml 1.0 M Tris/HCl [pH 6.8], 
0.1 ml 10% (w/v) SDS, 0.05 ml 10% APS, 5 μl TEMED 
 
Table 3.6. Buffers and components used for western blot analysis. 
3.1.5.3. Buffer for Immunofluorescence 
Buffers Ingredients 
Fixing buffer (/L) 1x PBS + 4% (w/v) PFA, adjust to pH 7.2 
Permeabilisation buffer 1x PBS + 0.2% (v/v) Triton X 100 
Blocking buffer 1x PBS + 10% (v/v) FCS 
Mowiol mounting medium 2.4 g Mowiol 488, 6 g glycerol, 6 ml H2O, 12 ml 0.2 M 
Tris/HCl adjust to pH 8.5 
 
Table 3.7. Buffers and components used for immunofluorescence analysis. 
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3.1.6. Commercial kits used 
Name Purpose Company 
TUNNEL Kit Cell death detection kit Roche 
Plasma membrane protein 
extraction kit 
Isolation of plasma membrane 
proteins 
Abcam 
 
Table 3.8. List of commercial kits used in this study. 
3.1.7. Inhibitors and Inducers 
Name Purpose Company 
TNF-α Apoptosis inducer BD Pharmingen 
LY294002 PI3 kinase inhibitor Cell signaling 
UO126 ERK inhibitor Cell signaling 
Dasatinib RTK inhibitor Cell signaling 
 
Table 3.9. List of inducers and inhibitors used in the study. 
3.1.8. Fine chemicals 
Compound Manufacturer 
Complete protease inhibitor Roche 
Phosphatase inhibitor Roche 
DRAQ5 BioStatus Limited, UK. 
ECL immunoblotting substrate Thermo 
Phalloidin Invitrogen 
LipofectamineTM 2000 Invitrogen 
 
Table 3.10. List of fine chemicals used in the study. 
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3.1.9. Antibodies 
Name 
(primary) 
Source Company Product# Dilution Application 
Actin Ms Sigma A5441 1:3000 WB 
IncA Rb This work -- 1:300 WB 
Pan-cadherin Ms Santa Cruz 59876 1:1000 WB 
Total Akt Rb Cell signaling 4685 1:1000 WB 
Total ERK Rb Cell signaling 9108 1:1000 WB 
EphA2 (D4A2)  Rb Cell signaling 6997 1:1000/1:200 WB/IF, FACS 
EphA2  Ms R&D MAB3035 1:200 FACS, IF 
PI3 Kinase p85 Rb Cell signaling 4292 1:300 WB, IP, IF 
PARP Rb Santa Cruz H-250 1:1000 WB 
Hsp60 Ms Santa Cruz 57840 1:1000, 1:200 WB, IF 
pAkt Rb Cell signaling 4060, 9275 1:500 WB 
pERK Ms Cell signaling 9106 1:500 WB 
Ephrin-A1 Ms Santa Cruz 377362 1:100 WB 
pEphA2 Ser897 Rb Cell signaling 6347 1:500 WB 
pEphA2 Tyr594 Rb Cell signaling 6347 1:500 WB 
EphA2 Rb Santa Cruz 924 1:1000 WB 
GP96  Ms Santa Cruz 53929 1:1000 WB 
PDI Ms Pierce (Thermo) MA3-019 1:1000 WB 
PDGFRβ Goat R&D AF385 1:1000 WB 
EphB4 Rb R&D AF3038 1:1000 WB 
 
Ms=Mouse, Rb=Rabbit 
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Secondary Antibody Source Company Dilution Application 
ECL α-mouse IgG 
HP linked 
Goat/Donkey GE healthcare 1:2500 WB 
ECL α-rabbit IgG 
HP linked 
Sheep /Donkey GE healthcare 1:2500 WB 
α-mouse Cy2/Cy3 linked Goat Dianova 1:200 IF 
α-rabbit Cy2/Cy3 linked Donkey/Goat Dianova 1:200 IF 
 
Table 3.11. List of primary and secondary antibodies used in the study. 
3.1.10. Recombinant proteins 
Recombinant human EphA2 (rhEphA2) and recombinant human Ephrin-A1 were purchased 
from R&D systems. Recombinant IgG1-Fc was bought from Life Technologies. 
3.1.11. Technical equipment and software used 
Equipments like Hera Cell 150 incubator (Thermo), Hera Cell sterile bench (Thermo), Rotanta 
460R centrifuge (Hettich), AvantiTM J-25I centrifuge (Beckman Coulter), cold centrifuge 5417R 
(Eppendorf), Owl Hep semidry electro-blotting system (Thermo), PerfectBlueTM Dual Gel Twin 
PAGE chambers (Peqlab Biotechnology), DM1500 confocal microscope (Leica), confocal Leica 
TCS SP5, DMR epifluorescence microscope (Leica), DMIL light microscope (Leica), Thermo-
mixer comfort (Eppendorf), 2720 Thermal cyclers (Applied Biosystems), Nano drop 1000 
spectrophotometer (Peqlab Biotechnlogy) were used. 
Software like Windows XP, Windows 7, Windows 8.1, EndNote X6 & X7, Microsoft PowerPoint 
2010/2013, LAS-AF confocal microscopy, Scaffold_4.3.2, Image J were used. 
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3.2. METHODS 
3.2.1. Cell Culture and bacterial infections 
HeLa 229 cells were cultured in RPMI (GIBCO) with 10% FCS and primary uterine tube 
epithelial cells (Fimb) were cultured in RPMI (GIBCO) with 10% FCS on collagen coated plates. 
HUVEC cells were cultured in medium-200 supplemented with low serum growth supplement. 
Cells were grown at 37°C and 5% CO2. The propagation of Ctr-LGV-L2 434/Bu, Ctr-serovar D, 
Ctr-serovar A, C. pneumoniae and the recombinant C. trachomatis strains [Ctr-pGFP::SW2, Ctr-
pIncA-flag] in HeLa cells were made as previously described [149]. Infected cells were then 
mechanically detached using a cell scraper (Sarstedt). The bacteria were released using ~5 mm 
glass beads (Carl Roth GmbH + Co. KG). Low-speed supernatant (5 min at 4000 x g and 4°C) 
was carried out to high-speed centrifugation (25 min at 40,000 x g and 4°C) in order to pellet the 
bacteria. Bacteria were washed twice with 10 ml SPG, aliquoted and stored at -80°C in SPG 
buffer and freshly thawed for each experiment. Cells were infected with Ctr with respective 
medium in the presence of 5% FCS and grown at 35°C with 5% CO2.  
3.2.2. Isolation of C. trachomatis intact inclusions 
Isolation and purification of the inclusions were performed as previously done [150] with 
modifications as below. HeLa cells were infected with C. trachomatis in T175 flasks (Corning) by 
adding a suspension of EB at a multiplicity of infection (MOI) 1 for 24 h. After washing both the 
uninfected and infected cells twice in the phosphate-buffered saline of Dulbecco lacking Ca and 
Mg (Life technologies), cells were detached using trypsin (Life technologies). RPMI containing 
5% FCS was added to the trypsinized cells and spinned down at 500 x g for 5 min at 4°C. The 
pelleted cells were washed thrice with PBS and centrifuged at 500 x g at 4°C. Cells were then 
re-suspended in sterile filtered swelling buffer containing 10 ml of 0.25 M sucrose-EDTA Tris 
buffer solution (1.5 mM EDTA in 10 mM Tris-HcL buffer, 5mM NaCl pH 7.4) and kept in ice for 
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90 min. To ensure better swelling, cells were mixed up and down in between with the pipette. 
The re-suspended cells were transferred to a glass dounce (10-15ml) and homogenized gently 
for 20 strokes. The homogenate was taken in a 10-ml plastic syringe and filtered the suspension 
though an 11 micron nylon filter (Millipore) having two filters in one cartridge on both sides of the 
rubber ring. This step can be repeated twice depending upon the cell status. The filtered cell 
suspensions were centrifuged at 500 x g for 5 min at 4°C. The supernatant was passed through 
a second glass membrane filter (Millipore Cat No: AP2001300). The collected supernatant was 
centrifuged at 4°C for 10 min at 1500 x g and washed twice with sterile filtered sucrose-Tris 
buffer (0.25 M sucrose in 10 mM Tris-HcL buffer). To the final washing step, sterile filtered 
Sucrose-Tris buffer containing 5% BSA was added to the pellet which were mixed gently and 
centrifuged at 1500 x g for 10 min at 4°C. (This step is not necessary if the protein lysate has to 
be prepared immediately in a denaturing condition). The purification procedure was monitored 
by light microscopy and confocal microscopy. The cell status was analyzed at each stages of 
purification. Pure inclusions were seen abundantly at the final stage of purification.  
3.2.3. Electron microscopy  
HeLa cells were infected with Ctr for 24 h. The infected cells were washed twice with PBS and 
fixed with 2.5% gluteraldehyde in 0.1 M sodium cacodylate buffer (pH 6.8) at 4°C for 1 h. The 
fixed cells were washed with cacodylate buffer and taken for preparation of the sample. 
Samples were transferred to the electron microscopy department (group of Prof. Dr. Georg 
Krohne) for further preparation.  
3.2.4. Preparation of intact Ctr inclusions for LC-MS/MS analysis 
Inclusion isolation procedure was performed for uninfected HeLa cells and C. trachomatis or C. 
trachomatis-GFP infected HeLa cells separately. For LC-MS/MS analysis, 2x Laemmli buffer 
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was added to break the inclusions. Purified materials from four biological replicates were 
prepared and sent to Greifswald proteome platform in a pack with dry ice.  
3.2.5. LC-MS/MS data analysis  
The following LC-MS/MS analysis was performed by AG Doerte Becher at Griefswald, 
Germany. Tryptic digests of the samples were subjected to liquid chromatography performed on 
an EASYnLC (Proxeon, Odense, Denmark) with in house packed columns (Luna 3μ C18(2) 
100Å, Phenomenex, Germany) in a one- column setup. Following loading/ desalting at a flow of 
700 nL/min at a maximum of 220 bar with water in 0.1% acetic acid, separation of the peptides 
was achieved by the application of a binary non-linear 70 min gradient from 5-50% acetonitrile 
in 0.1% acetic acid at a flow rate of 300nl/min. The LC was coupled online to an LTQ- Orbitrap 
mass spectrometer (Thermo Fisher, Bremen, Germany) at a spray voltage of 2.4kV. After a 
survey scan in the orbitrap (R = 30,000) MS/MS data were recorded for the five most intensive 
precursor ions in the linear ion trap. Singly charged ions were not taken into account for MS/MS 
analysis. The lock mass option was enabled throughout all analyses. 
After mass spectrometric measurement, MS-data was subjected to database searching via 
Sorcerer using Sequest (SageN, Milptas, CA, USA.) (Thermo Fisher Scientific, San Jose, CA, 
USA; version 27, revision 11) without charge state deconvolution and deisotoping performed. 
For database searching, a concatenated fasta database of Chlamydia trachomatis and a human 
database were used. Scaffold (version Scaffold_4.3.2, Proteome Software Inc., Portland, OR) 
was used to validate MS/MS based peptide and protein identifications. Peptide identifications 
were accepted if they exceeded specific database search engine thresholds. Sequest 
identifications required at least deltaCn scores of greater than 0.10 and XCorr scores of greater 
than, 2.2, 3.3 and 3.8 for doubly, triply and quadruply charged peptides. Protein identifications 
were accepted if they contained at least 2 identified peptides. Proteins that contained similar 
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peptides and could not be differentiated based on MS/MS analysis alone were grouped to 
satisfy the principles of parsimony. Purified materials from four biological replicates were 
analyzed by mass spectrometry and the Scaffold 4.3.2 program which displays a complete, 
experiment-wide view of the proteins (http://www.proteomesoftware.com/products/scaffold/).  
3.2.6. Chlamydia-IncA antibody production and purification 
The cytoplasmic domain of IncA of Ctr L2 strain was inserted into pGex4T3 vector (pGex4T3-
IncA-CP plasmid) which provides the inserted gene an N-terminal GST tag and an inducible lac-
promoter. The gene was cloned in frame into the pGex4T3 vector system with the restriction 
enzyme pair BamHI/ XhoI (cloning work done by Miriam Sturm). The sequenced vectors were 
eventually transformed into chemo-competent E. coli BL21 star and selected with ampicillin.  
In order to check the over-expression of the desired protein IncA-CP, the lac-operon of the 
pGex4T3 vector was induced with IPTG for 2 h. The bacteria was then pelleted and 
resuspended in Laemmli buffer for SDS- page analysis. For immunization, the purification was 
performed with 2 liters of induced culture. The collected pellet was then resuspended in ice- 
cold lysis buffer with lyzozyme and sarcosyl. Then the bacterial cells were disrupted by 2x 90 
seconds of sonification (50% intensity; 50% duty cycle at output control 4 sonifier (Branson, 
Sonifier B-12). Afterwards 200 ml of detergent buffer was added to the lysate and centrifuged 
for 10 min at 5000 x g and 4°C (Beckman Avanti, rotor JA-10). To the supernatant, triton-X 100 
was added and eluted using the elution buffer (50 mM Tris-HCl pH 8, 10 mM reduced 
glutathione, 100 µg/ml Lysozyme) for 20 min at 25°C in a thermomixer at 700 x g. The protein 
concentration was measured by Bradford assay and the eluted purified recombinant protein 
(referred as antigen) was sent to Gramsch laboratories for immunization to obtain the IncA 
polyclonal antibody serum. 
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The obtained polyclonal antibody serum was affinity purified to remove the unspecific antibodies 
obtained after immunization. The affinity purification was performed using antigen columns. The 
Cyanobromide (CnBr) beads (0.4 g) were swollen for 10 min in 1 mM HCl followed by one 
washing step using 0.2 M carbonate buffer. The buffer of the antigen was exchanged to 0.2 M 
carbonate buffer. The activated CnBr beads were immediately mixed with 300 μg antigen and 
incubated for 1 h at RT followed by 4°C overnight. Beads were then washed twice with 0.2 M 
carbonate buffer. The remaining coupling sites were blocked with 100 mM Ethanolamine for 1 h 
at RT. The beads were washed thrice with 0.2 M carbonate buffer followed by equilibration in 
500 mM NaCl in PBS and mixed with 10-20 ml serum. Affinity matrix and antibody serum were 
incubated at 4°C overnight on a rotary shaker. Beads were harvested by centrifugation at 500 x 
g for 5 min and 4°C and washed twice with 20 ml of 500 mM NaCl in PBS. The beads were 
transferred into a column and continuously washed using 150 ml of 500 mM NaCl in PBS. 
Antigen-specific antibodies were eluted under low pH with 0.2 M Glycine pH 2.5 and 
immediately neutralized by addition of 200 μl/ml of 1 M Tris HCl/pH 7.5. Fractions of the 
antibody elution were combined and concentrated using Amicon ultra centrifugation filter units 
with a molecular weight cut off of 10 kDa. Antibody fraction was finally mixed with one volume of 
87% glycerol and stored at -20°C.  
3.2.7. Adherence assay 
Ctr adherence assay was performed by pretreating the cells with rhEphrin-A1 (5 µg/ml) or with 
control (Fc) for 1 h at 37°C followed by infection with purified-EB for 1 h at 4°C in HBSS media 
(Life Technologies). Otherwise required MOI of EB were treated with rhEphA2 or with control in 
a serum free media containing 0.1% BSA for 1 h at 37°C and the mixture was added to the cells 
and incubated for 1 h at 4°C. Cell surface EphA2 was blocked using control (IgG) or antibodies 
against specific proteins (10 µg/ml) for 1 h at 4°C followed by infection with EB for 1 h at 4°C. 
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Before fixing the cells for immunostaining, cells were washed three times with PBS. Co-
localization of EB with EphA2 was determined manually by quantifying from 8 different fields of 
higher magnification view in 3 independent experiments where the samples were blinded. 
3.2.8. Pull-down assay 
To prove the direct interaction of EphA2 with Ctr-EB, pull-down assay was performed. Ctr-EB 
(L2) were purified as described before [151]. Purified Ctr-EB was incubated with rhEphA2 (10 
µg/ml) or with rhEphrin-A1 (10 µg/ml) in a serum free RPMI media containing 0.1% BSA for 45 
min at 37°C in a rotary shaker. Additionally, rhEphrin-A1-preincubated rhEphA2 was incubated 
with EB as above and the mixture was centrifuged at 5000 x g for 4 min at 4°C. The pellet was 
gently washed three times with ice cold-PBS by centrifugation at 5000 x g for 4 min at 4°C and 
subjected to WB analysis. 
3.2.9. Invasion assay 
Ctr invasion assay was performed by transfecting the cells with siRNA against luciferase gene 
(Luci) or EphA2 gene for 40 h at 37°C or treating the cells with IgG or α-EphA2 antibody for 1 h 
at 4°C as mentioned in the adherence assay. The bacteria of required MOI were incubated with 
cells for 4-6 h at 35°C. The cells were fixed with 4% ice cold PFA for 30 min at 4°C. The fixed 
cells were taken for immunostaining after permeabilisation. Invasion assay in EphA2 
overexpressed cells was performed after 40 h of EphA2-pcDNA3 transfection for flow cytometry 
analysis to determine the relative invasion rate of Ctr comparing to control empty-pcDNA3-
transfected cells under permeabilised condition. 
3.2.10. Infectivity assay 
Transfection and infection in HeLa cells were performed as described above. Supernatant from 
the primary infected cells was removed and the cells were washed with PBS. Cells from one set 
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of experiment were lysed with glass beads and the lysate was passed through a pipette several 
times. The suspensions were transferred to HeLa cells (1:200 dilution) for secondary infection. 
The next day, cells were ﬁxed with 4% PFA followed by immunostaining. Draq5 (DNA) was 
used for counterstaining of nuclei and Hsp60 antibody was used to stain the Ctr inclusion. 
Number of the inclusions was counted by analyzing on ﬁve random ﬁelds under the microscope 
and size of the inclusion was determined by ImageJ software (http://imagej.nih.gov/ij). 
3.2.11. Generation of Ctr expressing recombinant-IncA (Ctr-pIncA-flag) 
Full length IncA was fused with tag sequences (HA and Flag) by overlap PCR and inserted into 
pGFP::SW2 replacing GFP:CAT. The transformation of Ctr-L2 was performed as previously 
described [152]. The plasmid DNA (6 µg) and Ctr 1x107 IFU (transfection mixture) were mixed in 
CaCl2 buffer and incubated for 30 min at RT. The transfection mixture was added to McCoy 
cells and incubated for another 20 min followed by culturing in a T75 flask with fresh RPMI 
supplemented with 10% FCS. After 48 h, cells were lysed by sterile glass beads and the 
supernatant was used to infect the fresh cells which were cultured in the presence of 2 U/ml 
penicillin G and 2 µg/ml CHX and passaged every 48 h. When productive inclusions were 
visible, HeLa cells were used for infection and the concentration of penicillin was increased up 
to 50-70 U/ml to prepare the stock.  
3.2.12. Plasmids and transfection 
Expression plasmid EphA2 (full length ref NP_004422.2) was generated by PCR amplification 
using cDNA of pDONR223-EphA2 from Addgene (ID:23926). The resulted amplicon was 
inserted into the pcDNA3 plasmid (Invitrogen). Mutant EphA2 without cytoplasmic domain 
(EphA2ΔIC) was created by inserting the region of human EphA2 encoding amino acids 1-560 
into pcDNA3. Empty pcDNA3 was used as a control. p85-PI3K expression plasmid was 
purchased from Addgene (ID:11499). Transfection was performed using 1 µg/ml plasmid per 
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well in 12 well plate using Polyethyleniminde (PEI) and OptiMEM transfection medium (Gibco). 
Transfection medium was changed after 5 h. Infection was performed at different time points 
after 20 h of transfection.  
3.2.13. siRNA and transfection 
siRNA smart pool targeting EphA2 (siGENOME Human EphA2, 5 nmol, M-003116-02-0005) 
was purchased from Dharmacon. Pooled siRNA against PDI and PDGFRβ were bought from 
Santa Cruz. Cells at ~60% confluent were transfected at with siRNA (50 pmol/ml) using 
Lipofectamine 2000 (Invitrogen) and optimum. 8 h post transfection, medium was exchanged 
and 40 h post transfection, cells were infected with Ctr for different time points. siRNA targeting 
luciferase gene was used as a control, siLuci (Control): AACUUACGCUGAGUACUUCGA.  
3.2.14. Inhibitor assay 
Cells were pre-treated with DMSO control or dasatinib for 1 h at 37°C followed by infection with 
Ctr. Or 14 h infected cells were treated with DA for 10 h. After 24 h of total infection, protein 
lysates were subjected to WB analysis or immunostaining. Uninfected or infected HUVEC cells 
were treated with DMSO or PI3K inhibitor LY294002 or MAPK inhibitor UO126 for 10 h. EphA2 
plasmid-transfected HeLa cells were left uninfected or infected with Ctr for 24 h and treated with 
DMSO or UO126 for 3 h or 6 h. 
3.2.15. Flow Cytometry (FACS)  
For staining the surface exposed N-terminal EphA2, cells were grown in 6-well plates. After the 
respective time points of infection, cells were washed 3 times in ice cold PBS and detached 
using 5 mM EDTA at RT for 10-15 min. The cells were collected in Eppendorf tubes and 
washed 3 times in ice cold PBS containing 0.5% BSA (blocking buffer) by centrifugation at 350 x 
g for 4-5 min at 4°C. Cells were fixed with 4% paraformaldehyde (PFA) for 20 min at 4°C 
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followed by incubation with 2% FCS for blocking to prevent unspecific binding of the antibody to 
the cell surface proteins. Antibodies directed against EphA2 (R&D systems), were diluted 1:200 
in blocking solution and added to cells for 1 h at 4°C in the dark followed by a washing step in 
blocking buffer. Secondary anti mouse-Cy5 antibody (GE healthcare, 1:200) was incubated for 1 
h followed by two washing steps in PBS and then taken for flow cytometry analysis. Via FSC-A 
and SSC-A, population of intact cells was determined and 10,000 events per sample were 
analyzed using “FACS AriaIII” and the “BD FACS Diva” software for all experiments. “FCSalyzer 
0.9.3” software was used to create the overlay histograms. For surface EphA2, cells were not 
permeabilised whereas for detecting the total EphA2, cells were permeabilised using 0.2% 
Triton-X-100 in PBS. For analyzing the invasion rate of Ctr (invasion assay) in EphA2 
overexpressing cells, Ctr-GFP was used. GFP was excited at 488 nm and Cy5 at 647 nm, 
respectively. 
3.2.16. Apoptosis sensitization assay 
Transfection of the cells with siLuci or siEphA2 was performed as described above. Uninfected 
and Ctr-infected cells (MOI-1, 15-16 h) were induced to apoptosis with 50 ng/ml of human 
recombinant TNF-α and 5 µg/ml of cycloheximide (CHX) (Sigma) for 5-6 h. After the respective 
time post induction, the stimulated and control cells were fixed for immunostaining using TUNEL 
kit or subjected to WB analysis to determine the PARP, cleaved PARP (C-PARP), Hsp60 and 
Actin.  
3.2.17. Re-infection assay 
HeLa cells transfected with EphA2-pcDNA3 were first infected with Ctr (MOI-1) for 24 h followed 
by re-infection using EB (MOI-15) for 4 h. The cells were washed to remove the unbound EB 
and fixed for immunostaining against EphA2 (EphA2, red), Ctr (Hsp60, green) and Actin 
filaments (Phalloidin, blue). The total number of re-infected bacteria (both adherent and invaded 
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new EB) in EphA2 overexpressed and neighboring untransfected-infected cells were counted 
separately for quantification. 
3.2.18. Plasma membrane isolation 
Plasma membrane proteins were isolated using the plasma membrane protein extraction kit 
from Abcam. Cells were grown in 150 cm2 dishes and infected for different time points. The cells 
were scraped down and washed twice with ice cold PBS and resuspended in homogenizing 
buffer and homogenized for 30-50 strokes using a dounce homogenizer. 5% of the homogenate 
was collected as input. The homogenate was centrifuged to obtain total cellular membrane 
proteins in the pellet. The total cellular membrane proteins were subjected to further purification 
as described by the protocol of the supplier to obtain 10-100 µg of plasma membrane proteins in 
the pellet.  
3.2.19. TCA Precipitation 
Supernatants of the uninfected (UN) and time course infected samples were collected. Around 
250 µl of 72% TCA and 12.5 µl of 1% Na-deoxycholate were added to final volume of 1 ml and 
incubated on ice for 30 min followed by centrifugation for 30 min at 14,000 x g in cold centrifuge. 
The pellet was washed with 400 µl of ice-cold acetone followed by another centrifugation for 10 
min and then dried at 37°C for 5 min which was then resuspended by shaking for 15 min at 
65°C followed by WB analysis. 
3.2.20. Immunofluorescence (IF) microscopy  
The 4% PFA fixed cells were permeabilised using 0.2% Triton-X-100 for 30 min and blocked 
with 2% FCS for 1 h at RT. The cells were incubated with respective primary antibodies for 2 h 
at RT. After washing with PBS, cells were secondary stained with phalloidin (Cy5) and Cy2 
linked anti-mouse to stain the cell membrane and bacteria respectively for 1 h at RT. For 
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staining the adhesive bacteria on the cell surface, the PFA fixed cells were blocked with 2% 
FCS and stained for extracellular bacteria without permeabilisation. Samples were washed as 
above and mounted with Mowiol. The exposure time was same for all images in each set of 
experiments.  
3.2.21. Immunoprecipitation and Western blotting  
For immunoprecipitation, UN or Ctr-infected cells were washed once with PBS and lysed in 1% 
NP-40, 150 mM NaCl, 2.5 mM EDTA/EGTA, 20 mM HEPES pH 7.4. The lysates were cleared 
by centrifugation at 20,000 x g and supernatants were incubated with α-EphA2 or α-p85-PI3K 
antibody for 1.5 h and precipitated using magnetic beads. All the steps and buffers used during 
immunoprecipitation were carried out at 4°C with phosphatase and protease inhibitor (Roche). 
The precipitated complexes were subjected to WB and were resolved by 8-12% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes (Roche Diagnostics GmbH) and blocked with Tris-buffered saline 
containing 0.1% Tween 20 and 5% bovine serum albumin. Primary antibodies were incubated 
overnight at 4°C. Proteins were detected with peroxidase-coupled secondary antibodies using 
the ECL system (Pierce) and an Intas Chem HR 16-3200 reader. The signal bands were 
quantified by ImageJ software. 
3.2.22. Statistical analysis 
For statistical calculations and histograms, Excel (Microsoft) was used. Statistical significance 
was calculated using the Student’s T test. Two-tailed T test was performed to calculate the P-
value. 
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4. RESULTS 
4.1. Identification of host interacting proteins present in the isolates of Ctr 
inclusions by mass spectrometry 
4.1.1. Isolation of intact chlamydial inclusions from the infected cells 
Several host trafficking pathways are targeted and manipulated efficiently by the virulence 
factors of Ctr to acquire nutrients for their successful intracellular replication. The knowledge of 
how this pathogen can effectively control the signaling pathways and escape from the host cell 
death pathway depends on the identification and analysis of the host molecular factors that 
interacts with the Ctr inclusion. To study that, a methodology for the native Ctr inclusions 
isolation was established (described briefly in methods 3.2.2). Purification of the inclusions was 
performed by double filtrations and further centrifugations including washing steps with 
appropriate concentration of buffers in order to get the intact chlamydial inclusions.  
Phase contrast-light microscopy images that were taken during the process of inclusion isolation 
were shown in figure 4.1. Image 1 (Figure 4.1A) was taken when the cells were kept in the 
swelling buffer for 60 min in ice which leads them to swollen. The inclusions were clearly seen 
as bright bodies in the central region of the cytoplasm. Image 2 (Figure 4.1A) was obtained after 
strokes of homogenization followed by double filtration. Some debris were visible near to the 
inclusion which was removed by further washing and centrifugation steps. Finally, intact 
inclusions were obtained with some cell organelles attaching to the membrane of the inclusion 
which could not be avoided during invitro purification (Image 3 in Figure 4.1A). Therefore, 
uninfected cells were also purified similarly to eliminate the contaminating proteins. To further 
prove that the purified inclusions were still intact, GFP-positive Chlamydia (Ctr-GFP) was used 
[152]. As shown in figure 4.1B, it was clear that most of the inclusions were still intact (green 
arrows) with some disturbed inclusions which have left over RB (indicated in white arrows).  
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Figure 4.1. Monitoring the isolated chlamydial inclusions: (A) HeLa cells were infected with Ctr at 
MOI-1 for 24 h and the chlamydial inclusion purification was performed as described in methods. 
The purification procedure was monitored at each stage by phase contrast microscopy. Image 1- 1 
h incubation in swelling buffer, Image 2- Filtration, Image 3- Final step. Scale bar, 10 μm. (B) Ctr-
GFP inclusions were monitored by confocal microscopy showing the intact inclusions (green 
arrows) and disturbed inclusions with left-over RB (white arrows). Scale bar, 10 μm. 
Purity of the isolated inclusions was analyzed by immunoblot studies using the organelle 
markers. The total cell lysates of uninfected and Ctr-GFP-infected cells shows the presence of 
proteins of respective cell organelles as well as the chlamydial markers Hsp60 and IncA in the 
infected sample (Figure 4.2). After purification, chlamydial markers (Hsp60 and IncA) seen in 
the infected sample were similar to total cell infected lysates comparing to other organelle 
markers which shows the enrichment of the purified inclusions (Figure 4.2). 
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Figure 4.2. Immunoblot analysis of total cell lysates and lysates after purification of uninfected 
and infected HeLa cells: Markers for different organelles have been detected (Sam50-
mitochondrial marker, GPP130-Golgi marker, LaminB-Nuclear envelope marker, ERP72-
Endoplasmic reticulum marker). The host adaptor protein 14-3-3β has been shown to interact with 
the chlamydial inclusion [51] and was therefore used as a marker for chlamydial inclusion. 
The organelle markers were still present in the purified sample which could not be avoided in 
such type of filtration purification. Therefore, uninfected sample was also purified similar to 
infected sample to avoid the contaminating proteins that passes though the filter. To further 
investigate the purity of the inclusions, electron microscopy analysis was performed. The 
purified samples were prefixed using 2.5% gluteraldehyde in 0.1 M sodium cacodylate buffer 
(pH 6.8) and the post fixation was done by the core facility (Electron microscopy-Methods).  
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Figure 4.3. Electron microscopic analysis of pre-isolated inclusions: The image of the infected 
cells kept in swelling buffer. The membranes of the RB and EB inside the inclusion were swollen. 
RB-Reticulate body, EB-Elementary body, M-Mitochondria. Bars represent 2 μm at magnification 
6000× (left image) and 8000× (right image). 
The image of the infected cells kept in swelling buffer was shown in figure 4.3. The inclusion 
membrane, its association with mitochondria and Chlamydia-EB and -RB inside the inclusion 
was visible. Due to the cells incubation in swelling buffer, the membranes of both EB and RB 
were also swollen inside the inclusion (Figure 4.3). The inclusion membrane of the purified 
inclusions was completely broken off with left over EB and RB after processing the purified 
inclusions for electron microscopy analysis (Figure 4.4).  
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Figure 4.4. Electron microscopic analysis of post-isolated inclusions: The image was taken after 
purification showing only the membrane ruptured inclusions with enriched elementary and 
reticulate bodies that occurred due to the processing of pre- and post-fixation procedures for the 
electron microscopy analysis. Bars represent 6 μm at magnification 10,000×. 
The reason behind the damage of the inclusion could be the post fixation procedures for 
electron microscopy. However, the inclusions were intact immediately after the isolation 
procedure (Figure 4.1) and the rupture of the inclusion membrane happened only during 
electron microscopy processing. Therefore, purified inclusions were solved in Laemmli buffer 
and the proteome was analyzed by mass spectrometry. 
 
 
RESULTS 
68 
 
4.1.2. Mass spectrometry analysis of the enriched-isolated Ctr inclusions 
The experimental setup for the mass spectrometric analysis was described briefly in methods 
(3.2.4 and 3.2.5) and in figure 4.5. 
 
Figure 4.5. LC-MS/MS analysis of enriched Ctr inclusions: Samples from four biological replicates 
were analyzed by mass spectrometry and the Scaffold 4.3.2 program which displays a complete, 
experiment-wide view of the proteins.  
In total, 2671 proteins were identified of which 2231 were host proteins and 440 were Ctr 
proteins. The host proteins that are associated with the chlamydial inclusion were identified via 
mass spectrometry analysis after determining the fold change. Out of 2231 host proteins, 394 
proteins were enriched as defined >2 fold and 343 proteins were depleted as defined <0.5 fold 
in the membranes of the infected samples (data not shown). Accordingly, 737 differentially 
regulated proteins (enriched proteins + depleted proteins in the membrane of the inclusions) 
were identified (data not shown). Among them, 102 proteins (36 proteins were enriched and 66 
proteins were depleted) were reproducibly identified in all the samples. To further characterize 
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the role of these host cell proteins in the infection process, whole genome RNAi was performed 
[in collaboration with AG Thomas Meyer, MPI, Berlin (data not shown)] which helped to short list 
the host candidates for further analysis. 
4.1.3. Validation of identified host proteins associated with Ctr inclusions 
Protein targets that play a crucial role in the regulation of host cell metabolism and apoptosis 
were chosen for the validation studies because the important prerequisite for successful Ctr 
infection involves energy acquisition form host cell and inhibiting cell death. Five hits namely 
EphrinA2 receptor (EphA2), Protein tyrosine phosphatase mitochondrial 1 (PTPMT1), 
Hexokinase 1 (Hex1), A-kinase anchor protein 1 (AKAP1) and Era-like 12S mitochondrial rRNA 
chaperone 1 (ERAL1) were selected after comparing Ctr inclusion proteome data with RNAi 
data. 
EphrinA2 (EphA2) is a receptor tyrosine kinase whose expression is found in most cancers 
including lung, breast, ovary, prostate, colorectal, skin and esophagus [153]. Inhibiting EphA2 
by siRNA induces apoptosis and attenuates tumor growth in malignant mesothelioma [154]. 
PTPMT1, a protein tyrosine phosphatase, is a regulator of cardiolipin biosynthesis [155]. 
Cardiolipin is an important component of the mitochondrial inner membrane where it constitutes 
about 20% of the total lipid composition. Loss of PTPMT1 leads to dramatic diminution of 
cardiolipin. It also mediates dephosphorylation of mitochondrial proteins, thereby playing an 
essential role in ATP production [156]. Hexokinase 1 is an enzyme that phosphorylate glucose 
to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Hex1 
interacts directly with VDAC to induce channel closure and prevent the release of cytochrome c 
thereby inhibiting intrinsic cell death [157]. AKAP1 binds to type I and type II regulatory subunits 
of protein kinase A and anchors them to the cytoplasmic face of the mitochondrial outer 
membrane [158]. Protein kinase A has several functions in the cell, including regulation of 
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glycogen, sugar and lipid metabolism [Voet, Voet & Pratt (2006). Fundamentals of Biochemistry. 
Wiley. Pg 492]. ERAL1 is a GTPase that plays role in the mitochondrial ribosomal small subunit 
assembly. Depletion of ERAL1 leads to apoptosis, cell death occurs due to loss of mitochondrial 
protein synthesis or reduction in the stability of mitochondrial mRNA [159]. As a preliminary 
analysis, the protein expression of five host candidates during time course Ctr infection was 
checked by WB analysis (Figure 4.6).  
 
Figure 4.6. Protein expression analysis of the identified hits during Ctr infection: HeLa cells were 
uninfected (UN) or infected with Ctr at MOI-2 for different time points and the expression level of 5 
hits were analyzed by WB using respective antibodies. Hsp60 acts as a marker for Ctr infection 
and actin serves as a loading control.  
All the five host proteins were upregulated during time course Ctr infection. Of all the hits 
identified, EphA2, a cell surface tyrosine kinase receptor was found to be an attractive host 
target due to its increased expression level with increased time frame of Ctr infection as well as 
being a cell surface receptor. Therefore, further studies were designed to identify the 
importance of upregulated EphA2 during chlamydial infection. 
 
RESULTS 
71 
 
4.2. Role of EphA2 in early Ctr infection 
4.2.1. EphA2 is an adherence receptor for Ctr 
4.2.1.1. Ctr-EB interacts with EphA2 in an Ephrin-A1 sensitive manner 
Since EphA2 is a cell surface receptor, it was first investigated if EphA2 acts as a cellular 
receptor for Ctr. Therefore, adherence assay was performed at 4°C to prevent the uptake of 
adherent EB as previously described ([160]; methods 3.2.7). First, I tested if EB co-localize with 
EphA2 and if Ephrin-A1, a known ligand of EphA2 may interfere with EB-EphA2 co-localization.  
 
Figure 4.7. Interaction of EphA2 with Ctr-EB: (A, B) HeLa cells were pre-treated with control-Fc 
(purified Fc fragment) or Ephrin-A1-Fc (rhEphrin-A1) (5 µg/ml) for 1 h at 37°C and infected with Ctr 
(MOI-100) for 1 h at 4°C. Cells were fixed and immunostained for Ctr (Hsp60, green) and EphA2 
(EphA2, red). (A) Images show EphA2 or EB or the co-localization of EB with EphA2 (yellow) on 
the cell surface. (B) Co-localization of EB with EphA2 was quantified from 8 different fields of view 
in 3 independent experiments. The data are expressed as a mean percentage of EphA2-associated 
EB (± SD) compared to total EB. *P<0.05. Error bars show mean ± SD. 
Adherence assay performed confirmed the co-localization of EB with cell surface EphA2. The 
EB-EphA2 co-localization was reduced by 35% upon pre-treating the cells with the recombinant 
ligand Ephrin-A1-Fc (Figure 4.7A inset; Figure 4.7B). Binding of EphrinA1-Fc to the ligand 
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binding domain of EphA2 reduced the interaction of EB with extracellular domain of EphA2. 
These results suggested that EphA2 and EB interact on the surface of host cells in an Ephrin-
A1-sensitive manner.  
4.2.1.2. Ctr induces EphA2 activation upon binding on the cell surface  
In order to examine whether Ctr induces EphA2 activation upon infection, cells were transfected 
with EphA2 siRNA and the knockdown efficiency was monitored by WB analysis before and 
after infection (Figure 4.8A). Phosphorylation of EphA2 at Ser897 (pEphA2), indicative of 
receptor activation, was detected comparing to the uninfected control (Figure 4.8A). EphA2 
activation was detected close to adhering EB during the entry phase of chlamydial infection 
(Figure 4.8B), suggesting that interaction of EB with EphA2 induced receptor activation. As 
shown in figure 4.8C, approximately 23% EB co-localized with pEphA2. Cross-reaction of the 
pEphA2-specific antibody could be excluded since no signal was detected upon knockdown of 
EphA2 expression. Therefore, these results concluded that Ctr infection induces EphA2 
activation on the cell surface.           
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Figure 4.8. EphA2 activated upon early infection co-localizes with Ctr: (A) HeLa cells were 
untransfected (control) or transfected with siRNA against luciferase gene (siLuci) or EphA2 gene 
(siEphA2) for 40 h at 37°C. The transfected cells were uninfected or infected with Ctr for 15 min, 40 
min and 60 min. The knockdown efficiency was monitored by WB analysis. (B) Adherence assay: 
HeLa cells were transfected with siRNA against luciferase gene (siLuci) or EphA2 gene (siEphA2) 
for 40 h at 37°C. The transfected cells were infected with Ctr (MOI-100) for 1 h at 4°C followed by 
immunostaining Ctr-EB (Hsp60, green) and pEphA2 (phospho EphA2 Ser897, red). (C) Co-
localization of EB with pEphA2 was quantified. The graph was made similar to figure 4.7B. The 
data are expressed as a mean percentage of pEphA2-associated EB (± SD) compared to total EB. 
*P<0.05. Error bars show mean ± SD. 
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4.2.1.3. Direct interaction of cell surface EphA2 with Ctr-EB  
To test the direct interaction of EphA2 with EB, recombinant human EphA2 (rhEphA2) was 
incubated with purified EB in the absence of host cells. EB and rhEphA2 co-localized in this cell-
free assay (Figure 4.9A) and the co-localization was reduced when rhEphA2 was pre-incubated 
with the EphA2-ligand rhEphrin-A1 prior to incubation with EB (Figure 4.9B). Thus, the results 
confirmed the interaction of EB with EphA2. Direct interaction was further confirmed in a pull-
down experiment showing that purified EB interacts with purified rhEphA2 in a rhEphrin-A1-
sensitive manner (Figure 4.9C). These experiments clearly conclude the direct interaction of 
EphA2 with EB.  
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Figure 4.9. Ctr-EB directly interacts with cell surface EphA2: (A, B) EB were incubated with or 
without rhEphA2 (5 µg/ml) in a serum free RPMI media containing 0.1% BSA for 1 h at 37°C. 
Additionally, rhEphrin-A1-preincubated rhEphA2 was incubated with EB as above. The mixture 
was centrifuged onto coverslips, washed 3 times with ice cold-PBS, stained and quantified as 
Figure 4.7B. The data are expressed as a mean percentage of EphA2-associated EB (± SD) 
compared to total EB. *P<0.05, **P<0.01. Error bars show mean ± SD. (C) Pull-down assay: 
Purified-EB were incubated with rhEphA2 or with rhEphrin-A1 each 10 µg/ml in a serum free RPMI 
media containing 0.1% BSA for 45 min at 37°C in a rotary shaker. Additionally, rhEphrin-A1-
preincubated rhEphA2 was incubated with EB as above and the mixture was centrifuged at 5000 x 
g for 4 min at 4°C. The pellet was gently washed 3 times with ice cold-PBS. Ctr-infected cells act 
as a positive control for full length EphA2 expression. The samples were subjected to WB 
analysis to determine the full length endogenous EphA2 and rhEphA2 using N-terminal EphA2 
specific antibody. Hsp60 acts as a control for EB. 
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Further, pre-incubation of purified EB with rhEphA2 reduced the adherence of the EB to the cell 
surface by 36% compared to EB pre-treated with an unrelated His-tagged control protein, 
rhPHB (PHB-His)  (Figure 4.10A). Prohibitin (PHB) is a mitochondrial inner membrane protein. 
rhPHB acts as a control for His-tagged rhEphA2. These results suggested that EB adhere to 
epithelial cells via a bacterial ligand that interacts with EphA2, possibly via the ligand-binding 
domain of EphA2. Indeed, blocking the ligand-binding domain of EphA2 with an antibody 
directed against the N-terminus of EphA2 reduced adherence of EB to HeLa cells by 33% 
confirming a role of the ligand-binding domain in the EB-EphA2 interaction (Figure 4.10B).  
It was previously shown that the cell surface protein disulphide isomerase (PDI) enzymatic 
activity is required for chlamydial entry into cells [161]. Chlamydia do not appear to utilize 
plasma membrane–associated PDI as a receptor, suggesting that Chlamydia binds to a cell 
surface protein that requires structural association with PDI. Further, blocking cell surface PDI 
using PDI antibody did not affect the Ctr attachment [161]. Therefore, as a known control, PDI 
was blocked and found no reduction in Ctr adherence (Figure 4.10B). In addition, blocking an 
unrelated EphB4 receptor [142] had no effect on adherence of Ctr (Figure 4.10B). Thus, from 
the results, either blocking the extracellular domain of EphA2 by rhEphrinA1 or EphA2 antibody 
significantly reduced Ctr infection suggesting that EB directly interacts with EphA2 on the cell 
surface upon infection. 
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Figure 4.10. EphA2 is required for chlamydial adherence: (A) EB pre-incubated with rhPHB (PHB-
His) or with rhEphA2 (EphA2-His) each 5 µg/ml for 1 h at 4°C were added to HeLa cells for 1 h at 
4°C. Cells were fixed and immunostained for extracellular EB and actin filaments. The number of 
extracellular EB was counted randomly from 40 different cells. Data are expressed as percentage 
of extracellular EB relative to control. Shown is the mean ± SD of three independent experiments 
normalized to control+EB. *P<0.05. Error bars show mean ± SD. (B) HeLa cells were incubated 
with antibody against N-terminal-EphA2 or -PDI or -EphB4 each 10 µg/ml for 1 h at 4°C and were 
infected with GFP-expressing Ctr for 1 h at 4°C. Cells were fixed and immunostained against actin 
filaments (phalloidin). Graph was made similar to (A). Shown is the mean ± SD of two independent 
experiments normalized to IgG control. *P<0.05, **P<0.01, ***P<0.001.  
4.2.2. EphA2 is involved in host cell invasion of Ctr 
4.2.2.1. Cell surface EphA2 inhibition affects the invasion of Ctr-EB  
The role of EphA2 was then investigated for the uptake of Ctr by HeLa cells (referred to 
'invasion'). Invasion was analyzed by infecting cells for 4-6 h at 35°C to allow the uptake of the 
EB by the host cell (Figure 4.11).  
 
Figure 4.11. Representation for invasion assay: Cells transfected with siRNAs or preincubated 
with antibodies or inhibitors were infected with EB at 35°C for 4-6 h. 
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At this time period, EB transform to RB and thus the bacteria do not replicate at this stage of the 
developmental cycle. After silencing total EphA2 expression by siRNA transfection (Figure 
4.12A), Ctr invasion was reduced by 30% (Figure 4.12B). It was previously shown that PDI 
enzymatic activity is required for Ctr entry [161]. Silencing of PDI (Figure 4.12A) reduced the 
invasion rate of Ctr by 65% and by 87% if both EphA2 and PDI were silenced together (Figure 
4.12B) confirming a role of both proteins in the uptake of EB.  
 
Figure 4.12. EphA2 knockdown affects the invasion of Ctr-EB: (A) HeLa cells were transfected 
with siRNA against luciferease or EphA2 or PDI or EphA2 and PDI for 40 h at 37°C. The 
knockdown efficiency was monitored by WB analysis against total EphA2, PDI and GAPDH. (B) 
Transfected cells of A) were infected with Ctr (MOI 15-20) for 4 h at 35°C. The cells were 
immunostained against EB and actin filaments. Number of EB invaded the cell were counted from 
10 separate fields of view. Shown is the mean ± SD of three independent experiments normalized 
to siLuci-infected cells. *P<0.05, **P<0.01. Error bars show mean ± SD. 
The ligand-binding domain of EphA2 was blocked with an antibody directed against the N-
terminus of EphA2. This EphA2 antibody blocking experiment reduced the invasion of Ctr by 
30% in a biopsy-derived human fallopian tube epithelial cells (Fimb) which are the primary 
target cells of Ctr genital infections (Figure 4.13A and 4.13B), demonstrating that this is not a 
cell line specific effect. Thus, EphA2 is required for both, efficient adherence as well as invasion 
of EB, suggesting that it directly interacts with Ctr on the cell surface and this interaction is 
followed by the induced uptake of EB by the host cell. 
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Figure 4.13. Blocking EphA2 affects the invasion of Ctr-EB: (A, B) Fimb cells were pre-treated with 
control IgG or N-terminal specific antibody against EphA2 for 1 h at 4°C and then infected with Ctr 
(MOI-50) for 4 h. (A) Cells were immunostained against Ctr-EB (Hsp60) and actin filaments 
(Phalloidin) and (B) quantified by counting the invaded EB out of 30 different cells. Shown is the 
mean ± SD of two independent experiments normalized to IgG control. *P<0.05. Error bars show 
mean ± SD. 
4.2.2.2. EphA2 tyrosine kinase inhibitor “Dasatinib” affects Ctr invasion 
Induced uptake of receptor tyrosine kinases frequently requires the kinase function of the 
receptor [162]. To get a first hint whether the kinase activity of EphA2 is required for Ctr entry, a 
clinically approved small molecule EphA2 tyrosine kinase inhibitor, dasatinib (DA), was used 
[141, 163]. In comparison to the control treatment (DMSO), pretreatment of cells with 2.5 or 5 
µM DA significantly reduced the entry of EB by 73% or 97%, respectively (Figure 4.14A and 
4.14B). Although we cannot exclude a role of other DA-sensitive kinases like Src family kinases, 
BCR-ABL, KIT (a cytokine receptor) and PDGFR [164, 165], the drastic reduction in Ctr invasion 
after DA treatment demonstrates the functional relevance of RTKs for Ctr invasion. This result 
concluded the kinase activity of EphA2 is required for the Ctr entry. 
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Figure 4.14. Dasatinib affects the invasion of Ctr-EB: (A, B) HUVEC cells pre-treated with DMSO 
control and with 2.5 μM or 5 μM DA, respectively, for 1 h at 37°C were infected with Ctr (MOI-20) 
for 6 h. (A) Cells were fixed and immunostained as (Figure 4.13A). (B) Invaded Ctr was counted 
randomly from 20 different cells under the microscope. Shown is the mean ± SD of three 
independent experiments normalized to DMSO-treated infected cells. **P<0.01. Error bars show 
mean ± SD.  
4.2.3. Ctr Infection induces rapid EphA2 activation and quantitative receptor 
internalization  
4.2.3.1. Internalized EphA2 remains active inside the cell and co-localizes with Ctr  
Having found that the cell surface EphA2 is required for Ctr adherence and invasion into the 
cells, I next investigated whether the surface EphA2 upon binding with Ctr directly mediates the 
entry of Ctr into the cells. Activated EphA2 is located in the infected cell after receptor 
endocytosis. Interestingly, the internalized active EphA2 receptor localized directly to the 
invaded EB, but also accumulated close to the bacteria at 4-5 h post infection (p.i.) (Figure 
4.15). Thus, the internalized EphA2 is stabilized and continues to signal after endocytosis in Ctr-
infected cells. 
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Figure 4.15. Internalized EphA2 is active and co-localizes with Ctr: Invasion assay: Cells were 
transfected with siRNA against Luci gene (A) and EphA2 gene (B). The transfected cells were 
infected with Ctr (MOI-20-25) for 4-5 h at 35°C followed by immunostaining against phospho 
EphA2 (pEphA2), Ctr-EB (Hsp60) and actin filaments (Phalloidin). Arrows indicate the co-
localization of Ctr with pEphA2 (yellow).  
4.2.3.2 EphA2 overexpressing cells increases the invasion rate of Ctr  
EphA2 was overexpressed in cells to further substantiate its invasion supportive function and its 
association with invaded Ctr. The invasion rate of Ctr 6 h p.i. and total EphA2 was determined 
by FACS under permeabilized conditions to determine the total EphA2 levels. Increased EphA2 
expression was confirmed in EphA2-pcDNA3-transfected compared to the control-transfected 
cells (Figure 4.16A and 4.16C). Invasion of Ctr increased about 2-fold if EphA2 was 
overexpressed (Figure 4.16B and 4.16C). Consistent with the previous observation (Figure 
4.15), invaded Ctr co-localized with EphA2 inside the cell (Figure 4.16C, indicated by arrows). 
These results confirm that EB bind and activate surface EphA2, resulting in Ctr and receptor 
internalization. 
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Figure 4.16. EphA2 overexpression enhances the invasion rate of Ctr-GFP: (A, B) HeLa cells were 
left untransfected or transfected with empty-pcDNA3 or EphA2-pcDNA3 for 40 h followed by 
infection with Ctr-GFP (MOI-50) for 6 h. EphA2 expression (A) and invaded Ctr-GFP (B) were 
checked by FACS under permeabilised condition. The graph (B) shows the mean fluorescence 
value of the uninfected (UN) or infected cells under permeabilised condition compared to the 
respective controls. Shown is the mean± SD of three experiments.***P<0.001). (A, B) UN: 
uninfected, Iso: isotype and perm: permeabilised. (C) Empty-pcDNA3 or EphA2-pcDNA3 
transfected HeLa cells were infected with Ctr for 4 h (MOI-20). Cells were fixed for immunostaining 
against EphA2 (EphA2, red), Actin (Phalloidin) and Ctr (Hsp60). Arrows were drawn to indicate the 
co-localization of invaded Ctr with EphA2 (yellow).  
4.2.3.3. Surface expression of EphA2 rapidly changes upon early Ctr infection  
The results so far demonstrated that the surface EphA2 is required for Ctr adherence and 
invasion and that the kinase activity of EphA2 may be involved in the uptake of EB. If invasion of 
EB changes surface display of EphA2 during Ctr entry. Unexpectedly, surface display of EphA2 
increased as early as 30 min p.i.  but returned to basal levels by 3 h p.i.  as was determined by 
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FACS under non-permeabilized condition measuring surface exposed EphA2 only (Figure 
4.17A, B-curve chart and 4.17C-bar chart). This raised the question whether the rapid 
downregulation of surface EphA2 that follows the initial increase results from receptor 
internalization. FACS analysis under permeabilized conditions to detect surface exposed and 
internalized proteins showed an increased EphA2 signal at 3 h p.i. (Figure 4.17A, B-curve chart 
and 4.17C-bar chart). Since EphA2 in the supernatant of cells at this time-point could not be 
detected (Figure 4.17D), it was concluded that EphA2 was internalized into the cell.  
 
Figure 4.17. Ctr-induces receptor internalization during early infection: (A, B) HeLa cells 
uninfected (UN) or infected with Ctr (MOI-50-75) for 30 min or 3 h were analyzed via FACS for 
surface EphA2 under non permeabilised or total EphA2 under permeabilised condition. Controls 
were indicated on the left curve chart (A) and corresponding samples on the right curve chart of 
the same experiment (B). (UN: uninfected, Iso: isotype and perm: permeabilised). (C) Result of A,B 
were indicated in bar chart for better understanding. Shown is the mean ± SD of three 
independent experiments normalized to UN perm.  *P<0.05, ns: non significant. Error bars show 
mean ± SD. (D) Culture medium of the UN as well as time course (as indicated) Ctr-infected cells 
were collected and TCA precipitated. The precipitated lysates were subjected to WB analysis 
against total EphA2. 
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4.2.3.4. Unlike Ephrin-A1-induced EphA2 degradation, EphA2 is rapidly activated 
and not degraded during Ctr infection  
Internalization is probably mediated by binding of EB to the ligand binding domain of EphA2, 
since Ephrin-A1 ligand-induced aggregation of EphA2 on the cell surface has previously been 
shown to function as the internalization signal [166]. This ligand-induced activation of EphA2 
results in auto-phosphorylation followed by rapid degradation. In line with receptor activation by 
Ctr infection, increased EphA2 phosphorylation was observed, reaching a 9-fold increase as 
early as 15 min p.i. (Figure 4.18A and also 4.8A). Interestingly, in contrast to ligand-induced 
EphA2 degradation ([166] and Figure 4.18B), EphA2 was not degraded in the cell during Ctr 
infection. Total levels of EphA2 rather started to increase around 4 h p.i. (Figure 4.18A), 
implying that EphA2 signaling induced by Ephrin-A1 and EB interaction differs. In addition, the 
rapid increase and decline in cell surface exposed EphA2 during early infection time-points is 
independent of changes in total EphA2.  
 
Figure 4.18. Ctr-induces rapid EphA2 activation: (A) HeLa cells were UN or infected with Ctr (MOI-
50) for the indicated time points. The cells were immunoblotted against pEphA2 and Actin. The 
blot was stripped and reprobed for total EphA2. (B) HeLa cells were treated with control-Fc or 
Ephrin-A1-Fc for 3 h and were harvested for WB analysis. 
4.2.4. EphA2 activated by Ctr infection recruits and activates PI3 Kinase  
Infection with Ctr activates the RAF/MEK/ERK and PI3K/Akt pathways that support normal 
chlamydial development and keep the infected cell in an apoptosis resistant state [70]. The 
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pathway that leads to PI3K activation has not been identified so far in Ctr infection. Several 
studies in recent years have shown an association of activated EphA2 with PI3K [107, 109].  
 
Figure 4.19. EphA2 associates with pPI3K during early infection: (A) HeLa cells were UN or 
infected with EB for the indicated time points and immunoprecipitated (IP) with α-EphA2 or α-p85-
PI3K antibodies. The IP material was solved in 40 µl Laemmli (100%) and loaded 20 µl for WB 
studies (50%) or (B) immunostained using α-EphA2 and α-pPI3K for 2 h at RT followed by 
secondary staining with anti-mouse Alexa fluor 488 and anti-rabbit Alexa fluor 647 for the 
microscopic analysis, respectively.  
To reveal whether the activated EphA2 induced by Ctr infection interacts with PI3K, 
endogenous EphA2 or the endogenous p85 regulatory subunit of PI3K (p85-PI3K) was 
immunoprecipitated from the lysates of uninfected or Ctr-infected cells. Activated PI3K co-
immunoprecipitated with EphA2 and activated EphA2 co-immunoprecipitated with p85-PI3K at 
30 min p.i. and the activation of both proteins were increased when immunoprecipitated from 
cells infected for 2 h (Figure 4.19A). The interaction was further verified by microscopy showing 
the co-localization of EphA2 with activated PI3K after Ctr infection (Figure 4.19B). These results 
strongly suggested that EphA2 activated upon Ctr infection recruits and activates PI3K during 
early infection. 
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4.3. Role of EphA2 in mid-phase Ctr infection  
4.3.1. Intracellular EphA2 associates with Ctr inclusion during mid-phase of the 
Ctr developmental cycle and is prevented from re-translocating to the cell surface  
4.3.1.1. EphA2 upregulated and activated throughout the Ctr infection is 
intracellular 
To this point, all data on the role of EphA2 during chlamydial infection were obtained during the 
early phase of infection and prior to EB-RB transformation. However, the proteomics data 
(Figure 4.6) suggested that EphA2 is also associated with the inclusion during the mid-phase of 
infection (24 h p.i.) when RB fully replicate. Therefore the role of EphA2 during mid-phase Ctr 
infection was investigated. 
EphA2 is activated and upregulated not only in HeLa cell line (Figure 4.20) but also in primary 
cells like HUVEC and Fimb cells (Figure 4.20A-HUVEC and 4.20B-Fimb) upon infection, 
demonstrating that this is not a cell line specific effect. Further, the expression of PDGFRβ was 
tested, which has been shown to be a receptor for C. muridarum [37] and of PDI required for Ctr 
invasion [161] as well as of EphB4, which is not required for Ctr adherence (Figure 4.10B). In 
contrast to EphA2, PDGFRβ was downregulated during Ctr infection and no significant changes 
were observed for PDI or EphB4 expression (Figure 4.20C). The amount and phosphorylation of 
EphA2 increased during viable Ctr infection in HeLa, but not heat-killed bacteria (Figure 4.20D). 
These results strongly conclude that EphA2 is specifically upregulated and activated during Ctr 
infection. 
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Figure 4.20. Viable Ctr infection induces the expression and activation of intracellular EphA2 in 
different cell lysates: (A, B, C) HeLa or HUVEC or Fimb cells were UN or infected with Ctr for 
different time points and subjected to WB analysis to determine the expression of the proteins 
indicated. (D) Cells were UN or infected with viable Ctr or heat-inactivated Ctr (HI) (65°C, 30 min) at 
MOI-100 for 15 min or with MOI-2 for 24 h. Lysed cells were immunoblotted against pEphA2 and 
Actin. The blot was stripped and reprobed for total EphA2. Increased levels of total EphA2 upon 
15 min p.i. depend on the high MOI of 100 used in this experiment. 
In order to determine where the overexpressed and activated EphA2 is located in the infected 
cell during the mid-phase of Ctr infection, plasma membrane protein isolation was performed. 
Plasma membrane isolated from infected cells at those time points contained constant levels of 
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total and activated EphA2, suggesting that the basal levels of EphA2 and activated EphA2 at 
these time points were unchanged at the cell surface (Figure 4.21A and 4.21B).  
 
Figure 4.21. Ctr-induced EphA2 expression is intracellular: (A) HeLa cells were infected with Ctr-
EB for 14, 24 and 36 h. Input (5%) was taken after homogenization step (before plasma membrane 
protein isolation) and subjected to WB analysis to determine pEphA2, Hsp60, and Actin. The blot 
was stripped and reprobed for total EphA2. Numbers under the blot represents fold activation for 
pEphA2 with respect to total EphA2. (B) Plasma membrane protein was isolated from UN or Ctr-
infected cells at different time points and subjected to WB analysis. Pan Cadherin was used as a 
control for plasma membrane. IncA was used as a marker to test the quality of the isolated plasma 
membrane. * Unspecific bands detected by IncA polyclonal serum (C) Culture medium of the UN 
as well as time course Ctr-infected cells (as indicated) was collected and TCA precipitated. The 
precipitated lysates were subjected to WB analysis against pEphA2, total EphA2 and GP96. 
Further, the supernatants of the infected cells were precipitated to test if surface EphA2 is shed 
into the culture medium during infection as previously demonstrated for GP96 (Karunakaran et 
al., submitted). EphA2 was not detectable in the culture supernatant (Figure 4.21C), confirming 
that the increase in levels of EphA2 and activated EphA2 is restricted to the intracellular space. 
The levels of EphA2 on the cell surface as well as inside the cell during mid-phase Ctr infection 
were also determined by FACS analysis under permeabilised and non-permeablised condition. 
Surface EphA2 expression was similar at three different time points of Ctr infection (14, 20 and 
26 h p.i.) whereas permeabilised-infected cells (20 and 26 h p.i.) displayed a clear increase of 
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intracellular EphA2 levels (Figure 4.22). Thus, EphA2 upregulated during Ctr infection is 
intracellular and is prevented being translocated to the cell surface. 
 
Figure 4.22. Analysis of surface and total EphA2 expression during mid-phase Ctr infection: HeLa 
cells were infected with Ctr-EB (MOI-1) for 14, 20 and 26 h and cells were analyzed via FACS as 
Figure 4.17A. (UN: uninfected; perm: permeabilised). 
4.3.1.2. EphA2 is recruited to the inclusion membrane of Ctr 
To define the intracellular localization of EphA2, cells were first transfected with EphA2-pcDNA3 
and infected for different time intervals with Ctr. Overexpressed EphA2 was detected in the 
vicinity (6 and 16 h p.i.) and in association (24 and 40 h p.i.) with the inclusion (Figure 4.23A). 
Interestingly, the inclusion size appeared bigger in EphA2 overexpressing cells comparing to 
neighboring untranfected cells (Figure 4.23B), which shows the importance of EphA2 
intracellular signaling. However, it is not clear whether the internalized EphA2 is recruited by 
any inclusion specific membrane protein. 
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Figure 4.23. EphA2 associates with Ctr inclusion: (A) Cells were transfected with EphA2-pcDNA3 
and left uninfected (UN) or infected with Ctr (MOI-1) for different times as indicated. Cells were 
immunostained against EphA2 (red) and Hsp60 (Ctr, green). (B) Cells transfected with EphA2-
pcDNA3 were infected with Ctr (MOI-1) and immunostained against EphA2 (red), Hsp60 (Ctr, 
green) and DNA (Draq5, blue). Ctr inclusion of the untransfected cells (indicated with white 
arrows) were smaller than the inclusions of EphA2-transfected cells.  
To obtain the proof for the localization and activation of EphA2 around the inclusion membrane, 
the inclusion membrane-associated chlamydial IncA protein was fused to a HA and Flag tag in 
the plasmid pGFP::SW2 [152], replacing the GFP:CAT (Figure 4.24A). The Ctr strain expressing 
recombinant IncA-HA-Flag (Ctr-pIncA-flag) was confirmed by WB analysis (Figure 4.24B). In 
cells infected with Ctr-pIncA-flag, EphA2 was active (Figure 4.24C) and co-localized (Figure 
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4.24D) at the chlamydial inclusion membrane concluding that the inclusion-associated EphA2 
receptor is active. 
 
 
Figure 4.24. Association of EphA2 with Ctr inclusion membrane: (A) The vector map of 
pIncA::SW2 modified from the plasmid pGFP::SW2 [152] by replacing GFP:CAT with IncA-HA-
Flag. (B) HeLa cells were infected with Ctr wild type (WT) or Ctr-pIncA-flag for 24 h. Cells were 
lysed and the indicated proteins were detected by immunoblotting after separation on a 17% SDS 
PAGE gel to separate the endogenous IncA from the Ctr-pIncA-Flag expressing recombinant IncA. 
(C, D) HeLa cells were transfected with EphA2-pcDNA3 at 37°C and the cells were infected with 
Ctr-pIncA-flag for 24 h at 35°C. (C) Infected were fixed and stained against Flag (red), EphA2 
(green) and DNA (blue). (D) Infected were fixed and stained against Flag (red), pEphA2 (green) and 
DNA (blue). 
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4.3.2. Ephrin-A1 independent signaling takes place during chlamydial infection 
4.3.2.1. Chlamydial infection induces ligand independent signaling 
Ephrin-A1 ligand-mediated activation of EphA2 signaling inhibits both RAF/MEK/ERK and 
PI3K/Akt pathways whereas ligand-independent EphA2 signaling is important to promote those 
pathways [105, 110, 111]. Both ways of signaling are balanced in uninfected cells to maintain 
the cell homeostasis. To investigate whether Ephrin-A1-mediated EphA2 signaling takes place 
in Ctr infection, Ctr-infected lysates at different time points were collected and checked for the 
levels of Ephrin-A1. Levels of Ephrin-A1 were reduced in Ctr-infected HeLa cells and in primary 
HUVECs (Figure 4.25) at the indicated time points. Ephrin-A1 ligation with EphA2 induces 
phosphorylation of EphA2 at Tyr594 [167] and de-phosphorylation of EphA2 at Ser897 [104], as 
well as downregulation of EphA2 expression [168, 169]. In contrast, the data presented here 
shows that the EphA2 protein levels and phosphorylation at Ser897 were increased during Ctr 
infection in HeLa, HUVEC and also in Fimb cells (Figure 4.25). Thus, Ctr infection induces 
ligand-independent EphA2 signaling.  
 
Figure 4.25. Ligand independent EphA2 signaling takes place during Ctr infection: HeLa or HUVEC 
cells were uninfected or infected with Ctr at a MOI-1 for different time points and expression of 
different proteins were analyzed by WB. 
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4.3.2.2. Ephrin-A1-mediated EphA2 signaling affects Ctr infection 
To test whether Ephrin-A1-mediated EphA2 signaling affects Ctr infection or not, rhEphrinA1 
was used. Comparing to the untreated infected cell, rhEphrin-A1 treatment reduced the EphA2 
levels and subsequently reduced the primary and progeny infection (Figure 4.26A). The reduced 
Ctr primary infection in rhEphrin-A1 pre-treated cells was because of less availability of surface 
EphA2 for Ctr to invade the cell by considering the previous result (Figure 4.7A and 4.7B). From 
figure 4.21B and 4.22, the basal surface EphA2 levels in infected cells was detected similar to 
uninfected cells. Therefore, the rhEphrin-A1 presented in the culture medium might bind to the 
basal surface EphA2 and activates the reverse signal leading to the inhibition of pAkt and pERK 
survival pathways which further affects the invaded Ctr infection (Figure 4.26A and 4.26B).  
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Figure 4.26. rhEphrin-A1 pretreatment affects Ctr infection: (A) Cells were pre-treated with Fc 
control or rhEphrin-A1-Fc (15 µg/ml) for 2 h at 37°C and then uninfected or infected with Ctr (MOI-
1) for 28 h. Primary infected cell lysates were taken to infect the fresh cells for secondary infection 
(Infectivity assay). Cells were harvested to determine respective proteins by WB analysis. (B, C) 
Number and size of the inclusion per cell (%) for the infectivity assay were determined by Image J 
analysis. The graph was made after counting inclusions from 5 different microscopic fields in 3 
independent experiment whereas size of the inclusion was measured using cells out of four 
microscopic fields from 2 independent experiments (Error bars represent ± SD. ***P <0.001, 
**P<0.01).  
The interference of Ephrin-A1 signaling with Ctr infection was quantified. The number and size 
of the inclusions in HeLa cells were significantly reduced in rhEphrin-A1-treated cells comparing 
to the control-infected cells (Figure 4.26B and 4.26C). Thus, the high expression of EphA2 and 
low expression of Ephrin-A1 ligand could represent an advantage for Ctr infection. Hence the 
results provided the indication that Ephrin-A1-mediated EphA2 signaling acts negative for Ctr 
infection by preventing EphA2 from binding to its endogenous signaling ligands thereby 
suppressing the crucial signaling pathways required for Ctr infection. Thus, Ephrin-A1-mediated 
EphA2 signaling interferes with infection-induced PI3K signaling and Ctr infection. 
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4.3.3. EphA2 is required for long-lasting PI3K activation  
The rapid and strong activation of EphA2 by chlamydial infection and the association of EphA2 
with inclusions during the replicative phase of the developmental cycle suggested that EphA2 is 
required for chlamydial development, probably by signaling via PI3K. It is important to note that 
experiments conducted to investigate the role of EphA2 during the mid-phase of the chlamydial 
cycle were performed with a low MOI of 1-2 (in contrast to MOI of 50-100 for adherence and 
MOI of 20-50 for invasion experiments) to ensure similar initial infection irrespective of the 
EphA2 status (Infectivity assay-Figure 4.27 and methods 3.2.10). 
 
Figure 4.27. Infectivity assay: The transfected cells infected with Ctr (MOI-1) for 24 h at 35°C was 
referred as primary infection. The supernatant of the primary infected cells was taken to infect the 
fresh cells to determine the secondary infection. 
4.3.3.1. Interfering with EphA2 influences PI3K activation and Ctr infection 
To determine if changes in the expression of EphA2 influence Akt activation, EphA2 
overexpression by an expression plasmid and EphA2 knockdown by siRNA were performed. 
Indeed, EphA2 overexpression resulted in increased pAkt levels in uninfected cells which further 
increased upon Ctr infection [Figure 4.28(1)A]. In line with a role of EphA2 in PI3K activation 
also at the mid-phase of the chlamydial cycle, Akt activation was reduced upon knockdown of 
EphA2 in Ctr-infected cells [Figure 4.28(1)B]. Interfering with pAkt signaling by modulating 
EphA2 levels also influenced Ctr primary and progeny infection [Figure 4.28(1)A-E]. EphA2 
overexpression or EphA2 silencing changed the progeny infection by approximately 48% 
(increase during overexpression) and 37% (decrease during knockdown), respectively [Figure 
4.28(1)C and 4.28(1)D]. Number of inclusions in both primary (18% reduction) and secondary 
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infection [43% reduction, Figure 4.28(1)E] as well as the size of the inclusion in primary infection 
[40% reduction, Figure 4.28(2)B] were significantly affected upon silencing EphA2 expression. 
Further, silencing of PDGFRβ had no effect on PI3K activation and Ctr infection [Figure 
4.28(2)A and 4.28(2)B], demonstrating a specific role of EphA2 in Ctr infection. These results 
suggested that EphA2 activates the PI3K pathway and thereby supports chlamydial 
development.  
 
Figure 4.28(1). EphA2 overexpression and knockdown influences Akt activation and Ctr infection: 
(A) HeLa cells were transfected with empty pcDNA3 or EphA2-pcDNA3 each 1µg/ml and then left 
UN or infected with Ctr (MOI-1) for 24 h. Cells were harvested for WB analysis. (B) HeLa cells were 
untransfected (control) or transfected with siRNA against luciferase gene (siLuci) or EphA2 gene 
(siEphA2) for 40 h at 37°C and then left UN or infected with Ctr (MOI-1) for another 24 h. Cells were 
harvested for WB analysis. (C, D) Primary infected cell lysates of (B) and (C) were taken to infect 
the fresh cells for secondary infection (Infectivity assay). Numbers under the blot represents fold 
activation for phospho specific proteins with respect to total proteins and fold change for the total 
proteins. (E) Number of the inclusion per cell (%) for the infectivity assay was determined by 
counting inclusions on 10 independent fields. (Shown is the mean ± SD of three independent 
experiments normalized to control.  **P<0.01).  
 
RESULTS 
97 
 
 
Figure 4.28(2). Specificity of EphA2 on Akt activation and Ctr infection: (A) Cells were transfected 
with siRNA against luciferase (siLuci) or EphA2 (siEphA2) or PDGFRβ (siPDGFRβ) or both 
together for 40 h at 37°C and then infected with Ctr for another 20 h. UN: uninfected cells. Cells 
were harvested to determine the respective proteins by WB analysis. Numbers under the blot 
represents fold activation for phospho specific proteins with respect to total proteins and fold 
change for the total proteins. (B) Size of the inclusion per cell (%) for (A) was determined by 
ImageJ analysis by measuring cells out of four microscopic fields (Shown is the mean ± SD of two 
independent experiments normalized to siLuci.  *P<0.05).  
4.3.3.2. EphA2 interacts with PI3K and the complex associates with Ctr infection 
As increased Akt activation was found in EphA2–overexpressing-infected cells [Figure 4.28(1)A] 
and interaction of activated PI3K with EphA2 during early infection (Figure 4.19A and 4.19B), it 
was next determined whether increased total EphA2 during late Ctr infection also associates 
with activated PI3K. Co-immunoprecipitation experiment confirmed the presence of increased 
endogenous levels of activated PI3K with the immunoprecipitated endogenous EphA2 at 18 and 
24 h p.i, when Ctr has reached the replicative state (Figure 4.29A). The interaction was further 
verified by confocal microscopy showing the co-localization of EphA2 with activated PI3K after 
Ctr infection (Figure 4.29B), suggesting that PI3K activation is an important function of 
intracellular EphA2 in Ctr infection. 
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Figure 4.29. Interaction of EphA2 with pPI3K during mid-phase Ctr infection: (A) HeLa cells were 
left uninfected (UN) or infected with Ctr for the indicated period of times and immunoprecipitated 
using α-EphA2 antibody. The IP material was solved in 40 µl Laemmli (100%) and loaded 20 µl for 
WB studies (50%). (B) Cells were transfected with EphA2-pcDNA3 and p85-PI3K-expression 
plasmid together for 20 h followed by Ctr infection for 20 h. Cells were stained against EphA2 
(red), DNA (blue) and pPI3K (green). 
4.3.4. EphA2 intracellular cytoplasmic domain function is essential for chlamydial 
development 
4.3.4.1. Mutant EphA2 without the intracellular cytoplasmic domain affects PI3K 
activation and Ctr infection 
To identify whether the intracellular domain function of EphA2 is required for supporting Ctr 
development and PI3K activation, EphA2 deletion mutant lacking the cytoplasmic domain 
including the kinase domain (EphA2ΔIC) was constructed (Figure 4.30A).  
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Figure 4.30. EphA2 Kinase domain is crucial for Ctr infection: (A) Schematic representation of full 
length EphA2 plasmid and EphA2ΔIC plasmid which do not possess intracellular cytoplasmic 
domain. TM: transmembrane domain. (B) The plasmids having full length EphA2 or EphA2ΔIC 
were transfected and these cells were infected with Ctr for another 24 h. Cells were fixed and 
stained against α-EphA2 antibody (red) and Ctr using α-Hsp60 (green). (C) Arrows were marked to 
illustrate the difference between the size of the inclusion of untransfected (white arrows) and 
transfected (red arrows) cells. (D) Size of the inclusion was determined by ImageJ analysis. 
Empty-plasmid transfected cells act as a control. (Shown is the mean ± SD of two independent 
experiments normalized to empty-plasmid transfected cells.  *P<0.05, **P<0.01). (E) The cells after 
transfection followed by infection were subjected to WB analysis to analyze the proteins as 
indicated.  
RESULTS 
100 
 
EphA2ΔIC localized to inclusions like the wildtype form and was expected to function in a 
dominant-negative way by competing with the endogenous EphA2 receptors for binding to EB 
without activating downstream signaling pathways (Figure 4.30B). Transient overexpression of 
either EphA2 or EphA2ΔIC had a profound effect on the inclusion size. In cells transfected with 
full length EphA2, the size of the inclusion appeared bigger compared to the untransfected 
neighboring cells (Figure 4.30C and 4.30D). In contrast, the inclusion size appeared smaller in 
EphA2ΔIC transfected cells compared to untransfected cells (Figure 4.30C and 4.30D). These 
results clearly demonstrate the importance of EphA2 kinase domain for Ctr infection. 
Interestingly, levels of activated Akt were reduced in EphA2ΔIC transfected cells (Figure 4.30E) 
suggesting that EphA2ΔIC interferes with signaling of endogenous EphA2 in a dominant 
negative manner, e.g. by preventing functional dimer formation. 
4.3.4.2. EphA2 tyrosine kinase inhibitor “Dasatinib” affects mid-phase Ctr infection 
The RTK inhibitor dasatinib (DA) was used to further investigate the role of the kinase activity of 
endogenous EphA2 for Ctr infection. Pretreatment of cells with DA for 1 h followed by 24 h of 
infection inhibited EphA2 activation (Figure 4.31A) and strongly affected Ctr infection (Figure 
4.31B and 4.31C). DA may also inhibit other RTKs like PDGFRβ which has previously been 
shown to be required for C. muridarum entry [37]. However, PDGFRβ is rather downregulated 
during Ctr infection and additional silencing of PDGFRβ had no effect on Ctr-induced PI3K 
activation [Figure 4.28(2)A] or inclusion size [Figure 4.28(2)B]. Also, co-silencing EphA2 
together with PDGFRβ had no additive effect [Figure 4.28(2)], suggesting that Ctr does not 
employ the PDGFRβ during mid-phase infection.  
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Figure 4.31. Small molecule EphA2 inhibitor dasatinib affects Ctr infection: (A) HUVEC cells were 
pre-treated with DMSO(1) control or with 2.5 μM, 5 μM and 10 μM of DA, respectively, for 1 h at 
37°C and were infected with Ctr (MOI-1) for 24 h or the cells were first infected with Ctr for 14 h 
and then treated with DMSO(2) control or with 5 μM, 10 μM and 20 μM DA, respectively, for 10 h. 
Cells were harvested and immunoblotted against pEphA2 (Ser897) and IncA. The blot was 
stripped and reprobed for total EphA2 and Actin. (B, C, D) Experiments were performed as (A) and 
immunostained for Ctr inclusion (Hsp60, green) and DNA (Draq5, blue). (B) The size of the 
inclusion was measured by ImageJ analysis. Shown is the mean ± SD of two independent 
experiments normalized to control. **P<0.01.  
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To further substantiate a role of the EphA2 kinase activity for chlamydial replication and 
development, cells were infected with Ctr for 14 h followed by 10 h treatment with DA. These 
conditions allowed normal inclusion formation and EB to RB transition prior to the inhibition of 
EphA2 kinase during the replicative phase of Ctr development. This strategy did not only inhibit 
the Ctr-induced EphA2 activation (Figure 4.31A) but also reduced the Ctr infection in a dose-
dependent manner (Figure 4.31B and 4.31D). Akt phosphorylation was only mildly affected 
when DA was added at 14 h p.i. despite a reduction in Ctr infection (Figure 4.31A). Hence, 
these results demonstrate the importance of the kinase domain and activity of EphA2 for Ctr 
development. 
4.3.5. Ctr-induced EphA2 upregulation is mediated by ERK signaling  
The strong and long-lasting upregulation of EphA2 expression leading to its accumulation 
around the inclusion implied that infection-induced signaling pathways are involved. Therefore 
the role of the MAPK and PI3K pathways in upregulation of EphA2 during Ctr infection was 
investigated. Cells were left uninfected or infected for 14 h followed by treatment with MEK-1 
inhibitor U0126 (which blocks ERK activation) or the PI3K inhibitor LY294002 (which blocks Akt 
activation) to allow inclusion formation prior to application of chemical inhibitors. LY294002 
treatment after 14 h of Ctr infection did not affect total EphA2 levels or its activation whereas 
treatment with U0126 strongly reduced total and activated EphA2 levels (Figure 4.32A) and Ctr 
infection (see IncA in Figure 4.32A). This shows that MEK pathway plays a major role in EphA2 
expression during chlamydial infection. 
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Figure 4.32. Ctr-mediated EphA2 regulation is ERK dependent: (A) HUVEC cells were left 
uninfected or infected with Ctr (MOI-1) for 14 h followed by treatment with DMSO or PI3K inhibitor 
LY294002 (15 µM) or MAPK inhibitor UO126 (15 µM) for 10 h. After 24 h of total infection, cells were 
subjected to WB analysis against respective proteins. (B) EphA2 plasmid-transfected HeLa cells 
were left uninfected or infected with Ctr for 24 h as mentioned above the lanes. The uninfected or 
infected cells were treated with DMSO or UO126 (30 µM) for 3 h or 6 h as described above the 
lanes and subjected to WB analysis to determine the respective proteins as indicated. 
To discriminate if Ctr mediated-ERK activation is also essential for EphA2 activation (and not 
only for increased expression), EphA2 was overexpressed under the control of CMV promoter 
(pcDNA3 plasmid) and the effect of ERK inhibition before and after 24 h p.i., was investigated 
(Figure 4.32B). EphA2 overexpressed by transfection of an expression construct was not 
affected by ERK inhibition in both uninfected and Ctr-infected cells (Figure 4.32B). But 
interestingly, after ERK inhibition by UO126, the level of activated EphA2 was affected in both 
EphA2 transfected-uninfected as well as in 24 h Ctr-infected cells (lanes 2, 4 and 5 in Figure 
4.32B). These data suggests that Ctr mediated-ERK activation is necessary for the increased 
EphA2 expression and also for the activation of EphA2 during infection. 
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4.3.6. EphA2 is required to inhibit apoptosis signaling in infected cells 
Ctr infection is known to interfere with apoptosis signaling induced by various stimuli like 
staurosporine, etoposide, TNF-α, FAS antibody and granzyme B/perforin [53, 70]. Since EphA2 
plays a role in anti-apoptosis signaling [154, 170] and ERK pathway is required for Ctr-induced 
apoptosis inhibition [70] and EphA2 activation (Figures 4.32A and 4.32B), the role of EphA2 in 
apoptosis inhibition of infected cells was tested. Akt activation is dependent on EphA2 during 
mid-phase (16 to 24 h) but not late-phase Ctr infection (48 h) (Figure 4.33A), in line with its role 
in anti-apoptosis signaling during the replicative phase. Consistently, silencing of EphA2 
sensitized cells that had been infected for 16 h to apoptosis induced by TNF-α/CHX determined 
by PARP cleavage and apoptotic cell count (Figure 4.33B and 4.33C). Thus, EphA2-mediated 
signaling also supports apoptosis resistance of Ctr-infected cells, demonstrating its crucial 
intracellular role in Ctr infection. 
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Figure 4.33. Ctr-infected cells were sensitized to TNF-α induced apoptosis upon EphA2 
knockdown: (A) The transfection efficiency of siRNA directed against EphA2 was monitored by 
WB analysis against total EphA2. In addition, levels of pAkt, IncA and Actin were verified. (B) 
EphA2 knockdown followed by 16 h-infected cells were induced to apoptosis by TNF-α (50 
ng/ml)/CHX (5 µg/ml) for 5-6 h. Processing of PARP, Hsp60 and Actin was monitored by WB 
analysis. Rectangle boxes (black: before infection) or (red: after infection) denotes the difference 
in PARP cleavage after TNF-α induction in siLuci and siEphA2 transfected cells. (C) For 
quantification, TUNEL positive cells from each sample were counted from ten different fields. 
(Shown is the mean ± SD of two independent experiments.  **P<0.01, *P<0.05, ns: non-significant). 
4.3.7. Increased EphA2 expression during Ctr infection is prevented translocating 
to the cell surface to protect the intracellular niche 
It is not clear on how Chlamydia protects its host cell from competing re-infection. Our group 
found that Ctr prevents chlamydial re-infection in order to protect their intracellular niche 
RESULTS 
106 
 
(Karunakaran et al., submitted), probably to avoid competition for the nutrients. In order to 
examine the reason behind the prevention of EphA2 translocation to the cell surface of the 
infected cell, re-infection assay was performed. Re-infection assay performed in EphA2 
overexpressing cells showed 2.5 fold increased re-infection of new Ctr-EB in 24 h infected cells 
comparing to the untransfected infected cells (Figure 4.34A and 4.34B). Thus, to prevent the 
entry of new bacteria and to protect the intracellular niche, Ctr-infected cells might prevent 
EphA2 translocation to the cell surface apart from gaining EphA2 intracellular signals. The other 
reason might be to prevent EphA2 contact with its ligand Ephrin-A1 on the surface of 
neighboring cell which reverses EphA2 signaling of its own infected cell.  
 
Figure 4.34. EphA2 overexpressed infected cells allow re-infection in 24 h Ctr-infected cells. (A) 
Re-infection assay: Cells transfected with EphA2-pcDNA3 were infected with Ctr (MOI-1) for 24 h 
followed by re-infection using EB (MOI-15) for 4 h. Cells were washed thrice with PBS to remove 
the unbound bacteria and immunostained against EphA2 (red), Ctr (Hsp60, green) and Actin 
filaments (Phalloidin, blue). Microscopic view was made focusing on the newly re-infected Ctr 
(arrows). Nearby untransfected and EphA2 transfected cells (red) were shown in the same image 
with zoomed in white boxes for better magnification of invaded bacteria in EphA2 transfected 
cells comparing to the untransfected cells. Arrows were drawn to indicate the newly adhered or 
invaded Ctr. (B) The total number of re-infected bacteria (both adhered and invaded new EB) in 
EphA2 overexpressed and untransfected-infected cells were counted for maximum of 30 cells. 
Shown is the mean ± SD of three independent experiments normalized to untransfected infected 
cells.  **P<0.01. Error bars show mean ± SD. 
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4.3.8. EphA2 expression and activation in other chlamydial strains 
I next investigated whether EphA2 is also upregulated in other important chlamydial species like 
Chlamydia pneumoniae and in other Ctr-serovars like urogenital serovar D and ocular tract 
serovar A. Our preliminary analysis showed that EphA2 was upregulated and activated upon 
Ctr-serovar A, C. pneumoniae and Ctr-serovar D infected HeLa cells (Figure 4.35) like that of 
Ctr-L2.  
 
Figure 4.35. EphA2 expression and activation in Ctr-serovar A and C. pneumoniae-infected HeLa 
cells: HeLa cells were left UN or infected with Ctr-serovar A or C. pneumoniae or Ctr-serovar D 
and centrifuged at 910 x g for 30 min and allowed to infect for the indicated time points. The cells 
were harvested and subjected to WB analysis against pEphA2, Hsp60 and Actin. The blot was 
stripped and reprobed for total EphA2. 
4.3.9. EphA2 is an invasion and apoptosis resistance signaling receptor also for 
C. trachomatis-serovar D 
It was further tested if EphA2 can enhance Ctr-serovar D binding and invasion to HeLa cells like 
that of Ctr-L2. After silencing total EphA2 expression by siRNA transfection, Ctr-serovar D 
binding and invasion were reduced by 28% and 30% respectively (Figure 4.36A). Interestingly, 
like Ctr-L2, FACS analysis under non-permeabilised condition revealed an increased expression 
of surface EphA2 as early as 30 min p.i., but returned to basal levels by 3 h p.i., (Figure 4.36B). 
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FACS analysis under permeabilised conditions showed an increased total EphA2 signal at 3 h 
p.i., (Figure 4.36B). Thus, Ctr-serovar D also utilizes EphA2 to invade the cell. 
 
Figure 4.36. Ctr-serovar D utilize EphA2 for invading the cells and to prevent apoptosis induced by 
TNF-α: (A) HeLa cells were transfected with siRNA against luciferase gene (siLuci) or EphA2 gene 
(siEphA2) for 40 h at 37°C. Adherence assay: The transfected cells were infected with Ctr-serovar 
D for 1 h at 4°C. Cells were immunostained against EB and actin filaments. Number of 
extracellular EB was counted randomly from 30 different cells. Data are expressed as percentage 
of extracellular EB relative to siLuci. Shown is the mean ± SD of three independent experiments 
normalized to siLuci.  *P<0.05. Error bars show mean ± SD. Invasion assay: The transfected cells 
were infected with Ctr-serovar D for 4-5 h at 35°C. Cells were immunostained against EB and actin 
filaments. Number of invaded EB was counted randomly from 30 different cells. Data are 
expressed as percentage of invaded EB relative to siLuci. Shown is the mean ± SD of three 
independent experiments normalized to siLuci.  *P<0.001. Error bars show mean ± SD. (B) FACS 
analysis was performed with Ctr-serovar D infected cells as Figure 4.17A and 4.17B. (UN: 
uninfected, Iso: isotype and perm: permeabilised). (C) HeLa cells were left UN or infected with Ctr-
serovar D (MOI-1) for 14, 20 and 28 h and cells were analyzed via FACS as Figure 4.22. (D) EphA2 
knockdown followed by 16 h Ctr-serovar D infected cells were induced to apoptosis by TNF-α (50 
ng/ml)/CHX (5 µg/ml) for 5-6 h. Processing of PARP, Hsp60 and Actin were monitored by WB 
analysis. 
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To determine the surface and total levels of EphA2, FACS analysis was performed during mid-
phase Ctr-serovar D infection. Like Ctr-L2, the surface EphA2 expression was similar at three 
different time points of Ctr-serovar D infection (14, 20 and 28 h p.i.) whereas permeabilised-
infected cells (14 and 28 h p.i.) displayed an increase of intracellular EphA2 levels (Figure 
4.36C). Further, to find out the importance of internalized EphA2 in these cells, apoptosis 
sensitization assay was performed. The EphA2 silenced cells upon 16 h p.i. sensitized to TNF-
α/CHX induced apoptosis determined by PARP cleavage (Figure 4.36D). Thus, EphA2-
mediated signaling is essential for invasion and apoptosis resistance of Ctr-serovar D-infected 
cells, suggesting its crucial role as an entry and intracellular signaling receptor also in urogenital 
serovar of Ctr. 
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5. DISCUSSION 
First identified in a cancer cell line called erythropoietin-producing hepatocellular [171], 
numerous Eph receptors were subsequently detected, exhibiting diverse functions in vascular 
development, cancer and virus infection. This work reveals the identification of EphA2 as a key 
factor of Ctr entry and development using an unbiased approach, based on the compilation of 
data from hypothesis-free proteomics and RNA interference approaches. Interestingly no EphA 
receptors other than EphA2 were found in the proteomics approach (data not shown). Further, 
out of 14 Eph receptor genes validated in the initial RNAi screen, only silencing of EphA2 
revealed a strong inhibitory effect on infectivity (data not shown).  
5.1. EphA2 serves as an adherence and entry receptor for Ctr 
The receptors for Chlamydia are widespread on the surface of the epithelial cells. Several 
tyrosine kinase receptors like PDGFR and FGFR have been previously shown to be the 
receptor for C. muridarum, a mouse chlamydial pathogen. Further, interfering with epithelial 
membrane protein 2, a 4-transmembrane protein, affects C. muridarum infectivity [39]. The 
protein disulfide isomerase (PDI) [161] is required for C. trachomatis entry into cells and the 
mannose 6-phosphate receptor [172] influences C. pneumoniae attachment. But no receptors 
have been specifically found to be the direct interacting receptor for C. trachomatis on the cell 
surface. This study shows that the EphA2 receptor acts as a direct cellular receptor for Ctr and 
is activated upon infection. The adherence assay demonstrated that Ctr could bind to the ligand 
binding domain of EphA2 as blocking this domain by N-terminal specific EphA2 antibody or 
recombinant Ephrin-A1 affects Ctr adherence with the cell surface EphA2.  
Ephrin-A1 glycosylation is known to play an important role in binding and activating EphA2 
[173]. It was previously proposed that the outer membrane protein of Ctr is glycosylated [174] 
which further implicates that EphA2 may bind with high avidity to the glycoprotein complex of Ctr 
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and gets activated during the infection. Co-localization of EB with rhEphA2 was reduced upon 
incubating EB with rhEphrin-A1 pre-treated rhEphA2. This effect was further proven by invitro 
binding assay where the invitro enrichment of rhEphA2 precipitated together with EB. 
Additionally, the enrichment of rhEphA2 with EB was less when rhEphA2 was pre-incubated 
with rhEphrin-A1 which shows that EphA2 directly interacts with EB and is specific. In addition, 
pre-incubation of Ctr-EB with recombinant EphA2 or using N-terminal specific EphA2 antibody 
prevents the binding of Ctr with cell surface EphA2. This further confirms that EphA2 acts as an 
essential and direct adherence receptor for Ctr. 
Invasion assay studies performed using siRNA against EphA2 or antibodies directed against 
amino terminal-EphA2 or EphA2 tyrosine kinase inhibitor-dasatinib has affected Ctr invasion 
claiming to be also an important invasion receptor. Further in depth investigation of which Ctr 
factors, either the type three secreted effectors or the outer membrane protein complex, 
interacts and activates EphA2 to invade the cell has to be monitored. In addition, the signaling 
cascades formed during the infection downstream of EphA2 for invasion process should be 
identified via quantitative mass spectrometry analysis. This will unravel all the important early 
infection induced-interacting proteins of EphA2. Ctr attachment with host cell induces Rac 
activation [175] and Ephrin-A1 interaction with EphA2 induces Rac activation [176]. So Ctr by 
interacting with ligand binding domain of EphA2 may induce Rac activation during the early 
infection for the actin rearrangement and internalization process. Studies have to be performed 
to understand more on this which helps to disclose one way of Chlamydia invasion process.  
Ctr-serovar D which cause genital and perinatal infections [177, 178], also enhanced EphA2 
activation in infected HeLa cells. Similar to Ctr-L2, Ctr-serovar D also utilizes EphA2 for 
adherence and to invade the epithelial cells. EphA2 overexpression in majority of ovarian 
cancer patients predicts poor clinical outcome having shorter overall survival [120] and offer a 
hope of converting EphA2-targeted therapy into a clinical reality [179]. Ctr infections are known 
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to infect and damage human fallopian tube [180-183] and associates with ovarian cancer [184, 
185]. The preliminary findings using EphA2 blocking antibody in Fimb cells suggests that 
targeting EphA2 and other Eph receptors or co-receptors could definitely act as a tool to control 
Ctr-induced ovarian cancer. 
5.2. EphA2 internalizes during Ctr infection and associates with the inclusion  
So far the studies revealed the activation of EphA2 upon Ctr infection which starts as early in 
min post infection whose total level increases from 4 h post infection. Thus, viable Ctr when 
binding with cell surface exposed EphA2 activates EphA2 probably needed for their 
internalization process and this was not seen with heat-inactivated Ctr. This shows the 
specificity of the Ctr factor binding with cell surface EphA2 and activates it. More interestingly, 
FACS analysis, plasma membrane isolation and TCA precipitation studies performed showed 
the increased surface EphA2 expression upon 30 min post infection got decreased after 3 h 
post infection which is an indication that EphA2 is internalized together with Ctr. Hence, EphA2 
is necessary for Ctr invasion process in addition to the adherence process and the increased 
total EphA2 throughout Ctr infection is intracellular.  
EphA2 has been identified as a receptor for hepatitis C virus [141] and Kaposi’s sarcoma-
associated herpes virus [142] binding and entry. This study illustrates the function of EphA2 as 
a receptor for a bacterial pathogen. Though EphA2 acts as a cellular receptor for virus, nothing 
was known about its role during mid and later phase viral infection. Whereas in Ctr infection, 
both activation and total levels seem to increase throughout infection and is MOI-dependent. 
Unlike Ephrin-A1-ligand induced degradation of EphA2, Ctr infection upregulates and activates 
EphA2 throughout the infection. Thus, this work demonstrates a tyrosine kinase receptor’s 
function throughout a bacterial infection.  
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FACS analysis of mid-phase Ctr infection displayed similar EphA2 levels like that of uninfected 
cells, but showed increased EphA2 levels after permeabilisation stating that Ctr infection 
prevents the translocation of EphA2 to the surface and are kept intracellular for modulating the 
host signaling. Further, to prevent the re-infection and to protect the intracellular niche, Ctr-
infected cells prevents EphA2 re-localization to the cell surface because entry of new bacteria 
can cause host cell nutrients deprivation. It is not surprising to see an increased intracellular 
EphA2 expression during Ctr infection because EphA2 and its interacting proteins controls 
several cellular processes all of which are essential to oncogenic/survival pathways. 
Recruitment of active EphA2 to the inclusion membrane during mid-phase of infection cycle 
indicates that EphA2-mediated signaling occurs at the cytosolic side of the inclusion membrane. 
EphA2 may initially remain associated with the endosomal membrane during bacterial entry. It 
has to be investigated in future regarding how the receptor is recruited to the inclusion at late 
infection time points and whether this requires secreted chlamydial ligands. 
5.3. Association of EphA2 with p85-PI3K is crucial for successful Ctr infection 
Infection with Ctr activates both MEK/ERK and PI3K/Akt pathway to resist apoptosis during their 
infection. The factor upstream of PI3K activation was not known so far during Chlamydia 
infection. Several studies in past years have determined the association of activated EphA2 with 
p85-PI3K. This work revealed that EphA2 is an upstream factor of activated PI3K during Ctr 
infection. PI3K/Akt activation controls cellular phagocytic responses through multiple 
downstream targets, such as Ras and Rac, which are linked to actin polymerization and 
cytoskeletal dynamics [186, 187]. Chlamydia induces Rac activation for entry process [175]. 
Other gram-negative bacteria like Pseudomonas aeruginosa [188] and Salmonella typhimurium 
[189] also activates PI3K to gain the cellular entry. The flagellar motility of P. aeruginosa is 
linked to Akt activation in phagocytic cells and this activity is required for phagocytosis of 
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bacteria [188]. Activation of PI3K during chlamydial infection is, however, not completely 
dependent on activated EphA2 during chlamydial infection which indicates a possible role of 
other PI3K-inducing pathways. Recently, it was shown that EGFR is activated by Ctr infection 
and that Ctr-induced activation of Akt is EGFR-dependent [190]. Hence, apart from EphA2 and 
EGFR, there could be other tyrosine kinase receptors activated by Ctr that may also mediate 
Akt activation at different stages of their development.  
Although PI3K activation upon chlamydial infection was well known to promote cell survival, the 
pathogen recognition receptor-mediated PI3K signaling may contribute to host innate immune 
defenses. However, Chlamydia effectively overcomes host immune response probably by their 
secreting enzymes like chlamydial protease-like activity factor (CPAF) and ChlaDub1. CPAF, a 
protease, degrades the host DNA allowing the bacteria to evade the host immune system by 
delaying the activation of gene responsible for the production of its major histocompatibility 
complex [191].  In addition, another chlamydial enzyme named ChlaDub1 inhibits the NF-ƙB 
activation which play a crucial role in inducing the host inflammatory stimuli [192]. Further, it was 
known that constitutive activation of the PI3K contribute to reduce TLR4-mediated TNF-α 
release [193, 194]. EphA2 modifies the immune response by altering T cell recruitment and 
cytokine production during M. tuberculosis infection [148]. Thus, Chlamydia may efficiently avoid 
host cell immune response by the prolonged activation of EphA2/PI3K signal thereby enhancing 
the survival. 
5.4. Ctr-infected cells downregulates Ephrin-A1 to prevent the inhibition of host 
signaling pathway crucial for infection 
This profile of EphA2 upregulation induced by chlamydial infection is strikingly different from that 
observed after Ephrin-A1 stimulation. EphA2 is rapidly endocytosed upon Ephrin-A1 ligation and 
degraded in lysosomes [195]. This so-called ligand-dependent signaling involves 
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phosphorylation of EphA2 at Tyr594 [167] and interferes with the activation of the PI3K and 
MEK/ERK pathway [105]. The effect of Ctr infection on EphA2 is in line with ligand-independent 
signaling that causes EphA2 activation, supports PI3K/Akt activation and prevents EphA2 
degradation. 
 
Figure 5.1. EphA2 signaling in uninfected cell Vs Ctr-infected cell: Under normal conditions 
(uninfected cells),  EphA2 and Ephrin-A1 are properly expressed and engaged with each other on 
the cell surface which leads to balanced PI3K signaling which contributes to the maintenance of 
epithelial homeostasis. Ctr infection leads to down regulation of Ephrin-A1 and upregulation of 
EphA2. Activated EphA2 interacts and activates PI3K necessary for the infected cell survival. 
It was previously identified that EphA2 is a direct transcriptional target of the RAS-RAF-MAPK 
pathway [138]. Thus, infection induced ERK-mediates up-regulation of EphA2. This work shows 
that Ctr-mediated ERK activation, apart from transcriptionally regulating the expression of 
EphA2, also regulates the activation of EphA2. Hence, it is possible that ERK activation induces 
expression of any host protein which acts as a ligand in keeping EphA2 active during chlamydial 
infection. In addition to that, ERK activation is necessary for the Ctr infection and inhibiting ERK 
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activation by UO126 affects Ctr infection [65, 70]. In that case, some unknown chlamydial ligand 
might keep EphA2 active.  
The activation of the MAPK pathway inhibits levels of Ephrin-A1 [138]. Ephrin-A1 levels are 
reduced in Ctr-infected cells which show how Ctr can impede and modulate the host signaling 
pathways for their benefit (Figures 4.25 and 4.26). Thus, the reduced levels of Ephrin-A1 could 
be mediated by ERK activation during Ctr infection. The results are similar to glioblastoma cells 
and breast cancer cells where high levels of Ephrin-A1 exhibit low EphA2 and the condition is 
reversed by siRNA mediated knockdown of Ephrin-A1 [138]. In contrast, EphA2 overexpression 
exhibit low Ephrin-A1 [138, 139]. These findings propose a feedback loop mechanism also in 
Ctr infection which increases EphA2 expression and activation that leads to the suppression of 
its ligand (Figure 5.1). Thus, downregulation of Ephrin-A1 during Ctr infection is to prevent 
EphA2 interaction with EphrinA1, thereby preventing the EphrinA1-EphA2 mediated inhibition of 
PI3K and MAPK pathway crucial for Ctr infection. 
5.5. Ctr infection exploits intracellular EphA2 kinase function for enhancing the 
infection and inhibiting apoptosis 
Ctr mid-phase infection mediated-activation and -upregulation of EphA2 also associates with 
PI3K showing that Ctr uses EphA2 to control the downstream signaling throughout its infection. 
This association is definitely mediated by Ctr infection as knockdown or overexpression of full 
length EphA2 or mutant EphA2 lacking cytoplasmic domain influenced PI3K activation and 
further Ctr infection which collectively reveals an important role for EphA2 in productive Ctr 
infection. One could argue that the observed bigger inclusion in EphA2 overexpressing cells is 
due to the increased invasion rate of Ctr. But MOI-1-2 was used for all mid phase infection to 
ensure similar initial infection irrespective of the EphA2 status. Therefore the observed bigger 
inclusion in EphA2 overexpressing cells must be due to the EphA2–mediated downstream 
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signal which fastens the growth of Ctr. On the other hand, the smaller inclusion in EphA2ΔIC 
overexpressing cells could be missing of the EphA2 cytoplasmic domain mediated-downstream 
signals. Thus, the downstream signaling in overexpressed EphA2 fastens the Ctr infection and 
mutant EphA2 signaling slowed down Ctr infection.  
Both chemical inhibition of EphA2 kinase activity and of PI3K [70, 89] prevented Ctr infection if 
the inhibitor was added either prior to or simultaneously with infection. These effects were 
milder if the inhibitors were applied after the EB to RB transition. Therefore the early activation 
of the EphA2-PI3K pathway is important for chlamydial development. During this phase of 
infection, EphA2 levels remain largely unchanged indicating that post-translational modification 
by phosphorylation is the main mechanism of activation. During the middle and late phase of 
infection, the PI3K pathway appears to be less important since Ctr is able to develop 
irrespective of whether PI3K is active or not [70]. The dose-dependent downregulation of mid 
phase-chlamydial infection by dasatinib, which can inhibit the activity of EphA2, Src, BCR-ABL, 
KIT and PDGFR [164, 165], did not correlate well with the downregulation of the PI3K pathway. 
However, a kinase inactive EphA2 mutant also affected PI3K activation and Ctr infection, 
demonstrating a role of the EphA2 kinase activity in chlamydial infection. Clearly, the effect of 
the EphA2ΔIC was stronger suggesting, that the cytoplasmic domain of EphA2 in addition to its 
kinase activity has an important function. 
Ctr can replicate inside the host cell by preventing apoptosis. They are known to prevent 
apoptosis induced by various stimuli like staurosporine, etoposide, TNF-α, FAS antibody and 
granzyme B/perforin [53, 70, 196]. There are several accumulating evidences for EphA2 being 
an anti-apoptotic gene [154, 170]. Since the previous results showed changes in the activation 
of the survival signal (PI3K/Akt) upon EphA2 knockdown or overexpression, Akt activation in 
EphA2-siRNA transfected cells during mid to late phase Ctr infection was tested. Akt activation 
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was reduced in EphA2 knockdown cells during mid Ctr infection (16 h to 24 h) but not in later 
Ctr infection (48 h). Therefore, testing 16 h EphA2 knockdown Ctr-infected cells had underwent 
apoptosis induced by TNF-α demonstrating that EphA2 is required to maintain apoptosis 
resistance during Ctr infection. Similarly, Ctr-serovar D could also prevent cell death induced by 
TNF-α by EphA2 signaling. Thus, at least two different serovars of Ctr appear to be capable of 
amplifying EphA2 signaling crucial for infection.  
This function very likely depends on the role of RTKs in activation of the PI3K pathway which 
plays a role in at least two anti-apoptotic signaling pathways mediated by Ctr infection. The first 
pathway involves the inactivation of the pro-apoptotic BH3-only protein Bad [89]. The 
phosphorylated Bad gets dissociates from Bcl-2/Bcl-xL complex and the released Bcl-2/Bcl-xL 
inhibits Bax/Bak triggered intrinsic apoptosis. The second pathway involves the stabilization of 
the anti-apoptotic Bcl-2 family member Mcl-1 by Akt pathway [70], as interfering with Mcl-1 
levels sensitized Ctr-infected cells to apoptosis. 
It is very likely that maintaining apoptosis resistance supports the integrity of the host cell during 
chlamydial replication and thus supports the infection, although direct experimental proof for this 
hypothesis is missing. The crucial role of EphA2 for chlamydial replication and its long-lasting 
upregulation during the course of infection may have an important consequence. Taken 
together, the findings provide the first insight in the pathogenesis of Ctr where a host cell 
surface receptor is exploited for invasion and to facilitate the infection by exploiting the receptor-
mediated intracellular signaling cascades.  
5.6. Model: EphA2 signaling during C. trachomatis infection 
Chlamydial-EB interacts with EphA2 (may be also together with other co-receptors) expressed 
on the cell surface that facilitates the entry of EB inside the cell (probably by the known 
chlamydial effector proteins secreted though T3SS like TARP protein). This binding of Ctr-EB 
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with EphA2 recruits and activates the PI3K pathway via C-terminal SH2 domain of the p85 
subunit of PI3K [197]. The p85 subunit of PI3K binding to the intracellular domain of EphA2 
leads to conformational changes in the catalytic domain of PI3K (p110) and this leads to 
consequent kinase activation. The recruitment of EphA2 interacting with PI3K will help 
Chlamydia to use-up the downstream activated Akt pathway to inhibit apoptosis. Ctr infection-
induced activation of MEK/ERK pathway enhances the transcription rate of EphA2. The ligation 
of EphA2 with Ephrin-A1 antagonizes other growth factor and receptors mediated activation of 
MAPK signaling [198, 199]. Therefore by inhibiting the expression of Ephrin-A1, Chlamydia can 
effectively block the Ephrin-A1-EphA2 signaling mediated inhibition of PI3K/MAPK signaling 
pathway. EphA2 which interacts with PI3K are recruited to the chlamydial inclusion through 
unknown signaling caused by chlamydial secreted effectors. By recruiting EphA2 together with 
PI3K, chlamydial controls and benefits the downstream Akt signaling pathway (Figure 5.2).  
Apart from the PI3K, there are several other downstream targets of EphA2 like Ras-GTPase 
activating protein (RasGAP), Src, Abl family of non-receptor tryosine kinases and Rac1. During 
chlamydial infection, the Src kinase FYN has been shown to be essential for sphingomyelin 
trafficking to the Ctr inclusion  [50]. Moreover, Rac1 activation is involved in chlamydial invasion 
into the host cells [200]. In addition, EphA2 is required for the association of Rab5 with 
internalized KSHV and productive trafficking of KSHV [109]. Further, Eph-EphA2 complexes are 
shown to be involved in various forms of endocytosis and cellular trafficking pathways [95]. 
Thus, the central role of EphA2 in cytoskeletal regulation and intracellular trafficking may be 
exploited by Ctr for efficient cell entry, replication and development. Taken together, EphA2 acts 
as a critical invasion receptor as well as an intracellular master regulator receptor essential for 
Ctr. 
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Figure 5.2. Schematic representation of EphA2 signaling during C. trachomatis infection: (1) Ctr-
EB binds EphA2 and enters the cell with the activated receptor which interacts with and activates 
PI3K. (2) Ctr-mediated ERK activation induces EphA2 upregulation and activation. (3) Upregulated 
EphA2 is prevented from transporting to the cell surface. (4) Intracellular EphA2 is associated with 
the Ctr inclusion which interacts with p85-PI3K. (5, 6) EphA2-mediated downstream signaling 
cascade (pAkt) prevents apoptosis and enhance the infection. 
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6. OUTLOOK 
Successful infection by intracellular bacterial pathogens needs cellular adherence and invasion 
followed by intracellular multiplication and development by procuring nutrients through 
manipulation of host cell signaling pathways. This mechanism of bacterial attachment and 
successive ingress into the cells remains unclear. Anti-bacterial strategies could be developed 
once the host factors that are exploited by bacteria for the adherence and invasion process 
were identified and blocked. The present study was an attempt to investigate and understand 
the molecular mechanisms of a tyrosine kinase cell surface receptor, EphA2 that governs Ctr 
infection. The importance of EphA2, besides being an entry receptor, as an intracellular 
signaling receptor for Ctr survival was identified. 
The role played by EphA2 in other serovars like serovar A-C which causes infection in the eye 
and in other Chlamydia species like C. pneumoniae, a major cause of pneumonia have to be 
investigated. Human Herpes viruses and Chlamydia are both detected together in different 
human disorder like chronic fatigue syndrome [201]. In the preliminary studies, Ctr co-infection 
with HHV-6 showed decrease in EphA2 regulation compared to only Ctr infection which further 
illustrates the specific importance of EphA2 in Ctr infection. More studies have to be performed 
on this direction to understand the precise role of EphA2 during Ctr and HHV-6 co-infection.  
EphA2 was previously identified as GP96 client protein which is an essential mediator of EphA2 
stability and function [202]. Our group identified that GP96 plays a crucial role for epithelial cell 
infection with Ctr (Karunakaran et al., submitted). Therefore, GP96-dependent targeting of 
EphA2 may represent an important therapeutic strategy to impair EphA2 signaling essential for 
early Ctr infection. It is well known, that 50% to 70% of the patients infected with sexually 
transmitted Ctr are also positive for the Neisseria gonorrhoeae, a bacterium that causes 
gonorrhea in more than 100 million patients every year [203]. The reason for this high co-
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infection incidence is unknown. Interestingly, our group (Karunakaran et al., in preparation) 
found that Chlamydia-infected cells with down regulated GP96 are highly susceptible for N. 
gonorrhoeae infection. Preventing GP96 depletion and shedding prevents gonococcal co-
infection, but increases chlamydial re-infection and potential competition for host cell nutrients. 
Despite the observation that EphA2 expression is increased upon N. gonorrhoeae infection 
[140], the role played by EphA2 in the pathogenesis of N. gonorrhoeae has not been examined. 
Hence this needs further investigation. 
The role of other Eph receptors and its downstream signaling whether or not regulated during 
Ctr infection has to be explored. This study could be further expanded to mouse models to 
understand the role of EphA2 invivo. Targeting EphA2 and probably other Eph receptors could 
be a therapeutic base to control Ctr infection. Most importantly, the bacterial effector/s that 
interacts with EphA2 has to be investigated. Furthermore, the important question how EphA2 is 
recruited to the inclusion and whether they play any role in Ctr intracellular trafficking should be 
studied.  Thus, I have developed a working model to guide for additional studies to understand 
more of the role played by EphA2 signaling during Ctr infection. Further studies are vital to 
interpret the downstream targets of EphA2 that favors Ctr infection. Identiﬁcation of RTKs would 
be an important host factor regulating Ctr infection and thus targeting RTKs would be a 
promising therapeutic tool for controlling Ctr infection.  
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